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Abstract 
Background: People with AIDS (PWA) are at increased risk for certain types of cancer. The 
objective of the present study was to describe three aspects of the cancer epidemiology among 
PWA: time trends, risk and survival. 
Methods: To identify PWA who had cancer, a probabilistic record linkage between the 
databases “Information System on Disease Notification (SINAN)” (87,109 records) and the 
“Population-based Cancer Registry of São Paulo” (628,161 cancer cases) was conducted. The 
trend analyses were based on the annual percent change (APC) and corresponding 95% 
confidence intervals (95% CI). To assess the risk for cancer the standardized incidence ratio 
(SIR) and 95% CI were calculated. The survival analyses were conducted by means of Kaplan 
Meier methods and Cox models. 
Results: The database comprised 2,074 cancer cases, diagnosed in 2,000 PWA (seventy-four 
people had two primary site tumors). The majority were male (1,461; 73.0%), white (1,111; 
55.6%) and aged 30-49 years old at cancer diagnosis (1,257; 62.9%). Most cancers (1,057; 
51.0%) were non-AIDS defining (NADC). A statistically significant decline in the incidence of 
AIDS-defining cancers (ADC) was found in males and females (APCM = -14.1%/year; APCF = 
-15.6%/year). Conversely the incidence of NADC has increased since the mid 2000’s (APCM =
7.4%/year) among men. The risks for both ADC (SIRM = 27.74; SIRF = 8.71) and NADC (SIRM 
= 1.87; SIRF = 1.44) were significantly elevated. The overall five-year survival in PWA after 
cancer diagnosis was 49.4% (versus 72.7% in matched non-PWA). The hazard ratios were 2.93 
and 2.51 for ADC and NADC, respectively. 
Conclusion: Cancer burden among PWA in São Paulo was similar to that described in high-
income countries following the introduction of the highly active antiretroviral therapy. Despite 
the significant reductions in the incidence of ADC, PWA remain at higher risk of developing 
cancer. 
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1. Introduction
The association between human immune deficiency virus (HIV)/ acquired immune deficiency 
syndrome (AIDS) and cancer has been documented since the initial years of the AIDS epidemic. Kaposi 
sarcoma (KS) was one of the first signs indicative of immune suppression. In 1982, the first case 
definition of AIDS, in addition to Kaposi sarcoma, listed certain types of non-Hodgkin lymphoma (NHL) 
as possibly AIDS-defining conditions. In the same document, the Centers for Disease Control and 
Prevention (CDC) reported that between June 1981 and September 1982, 593 cases of AIDS had been 
identified in the United States, of which 37% had Kaposi sarcoma [1]. Only in 1993, was cervical cancer 
(CC) added to the list of as AIDS-defining conditions. Since then, AIDS-defining cancers (ADC) include
Kaposi sarcoma, non-Hodgkin lymphoma and cervical cancer [2]. 
The advent of the highly active antiretroviral therapy changed the course of the AIDS pandemic 
when it became widely available. Incidence of AIDS-defining illnesses, rates of hospitalization and 
mortality among HIV-infected people have all dramatically fallen after the introduction of highly active 
antiretroviral therapy [3, 4]. As a consequence, survival of these individuals significantly improved. 
Recent studies revealed that the life expectancy in this population is now comparable to that of the 
general population [5-8]. 
The incidence of AIDS-defining cancers has followed a similar decreasing pattern. In the United 
States, between 1980 and 2002, incidence of both Kaposi sarcoma and non-Hodgkin lymphoma 
significantly declined and the incidence of cervical cancer remained stable throughout the period [9]. On 
the other hand, incidence of particular non-AIDS-defining cancers, such as anal and liver cancers, has 
shown opposite upward trends [10, 11].  
In assessing the risk of cancer in the HIV-infected population in comparison to the general 
population, several studies revealed significantly higher rates in the first group. As in other populations 
with iatrogenic immune suppression, virus-related cancers account for the majority of excessive cases 
among HIV-infected patients [12].  
Concerning survival after cancer diagnosis, a limited number of studies have been conducted 
worldwide. Survival seems to be impaired in this population, but the disparities may greatly differ 
according to cancer site/type [13, 14]. 
Nevertheless, these studies were mainly restricted to high-income countries and cancer burden 
may differ in other regions for several reasons, including access to antiretroviral therapy and 
characteristics of the population living with AIDS [9].  
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2. Rationale and Objectives
The majority of the studies assessing cancer spectrum in the HIV-infected population have been 
conducted in developed countries, especially the United States and Italy. The disproportional number of 
studies conducted in these countries was possible due to the co-existing population-based cancer and 
AIDS registries. Unfortunately, in many countries, population-based registries are nonexistent and 
therefore epidemiological studies of this nature are not feasible. The city of São Paulo in Brazil, however, 
has an active population-based cancer registry, and AIDS notification has been mandatory since 1986. 
After the case definition for AIDS was released  in 1982, the first cases of the syndrome were 
soon identified in Brazil, with predominance of the city of São Paulo. A case that had occurred in 1980 
fulfilled the criteria for AIDS and was retrospectively classified as such. Until the end of the 1980’s, the 
city accounted for almost 40% of all notifications in Brazil, but with the increasing number of cases found 
in other cities, the proportion dropped to less than 7% in 2013. When considering the entire period (1980-
2013), the city concentrated over 12% of all cases diagnosed nationally [15]. 
In an effort to provide information on cancer among people with AIDS in a middle-income 
country, the project entitled “São Paulo AIDS-Cancer Linkage Study” was conceived. This is the first 
population-based study in Brazil describing cancer incidence in this population and one of few to be 
conducted in a developing nation. As part of this project, the objectives of this thesis were as follows: 
1. To assess trends in the incidence of AIDS-defining, non-AIDS-defining and the most frequent
cancers among people with AIDS, between 1997 and 2012, stratified by sex and compare those to that of 
the general population of the same geographical area (city of São Paulo). 
2. To compare the risk for cancer among people with AIDS after stratifying for sex, to that in the
general population. 
3. To describe the five-year overall survival after cancer diagnosis in people with AIDS and
contrast this to that of selected controls (without AIDS) from the general population. 
Each of the aforementioned objectives originated a separate manuscript; the three of them are part 
of this thesis, published as: 
 Manuscript one - “Trends in the incidence of AIDS-defining and non-AIDS-defining cancers
in people living with AIDS: a population-based study from São Paulo, Brazil” by the
“International Journal of STD & AIDS” (January, 2017).
 Manuscript two - “Risk for cancer among people living with AIDS, 1997-2012: the São Paulo
AIDS-cancer linkage study” by the “European Journal of Cancer Prevention” (January, 2017).
The third manuscript entitled “Cancer survival in people with AIDS: A population-based study 
from São Paulo, Brazil” was submitted on April 25th, 2017 to the International Journal of Cancer and was 
accepted on September 20th, 2017. 
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3. Methods
The analyses of the present study are based on residents of São Paulo who had cancer and AIDS. 
To conduct such a study, the database Sistema de Informações de Agravos de Notificação (SINAN)/ 
Information System on Disease Notification database (87,109 records) and the “Population-based Cancer 
Registry of São Paulo” (628,161 cancer cases) were linked using a probabilistic method. This design is 
known as population-based registry linkage study and it is a useful tool to examine cancer burden in 
people living with HIV/AIDS. It has been employed in other countries, such as Italy, Spain and the 
United States, among others [9, 10, 13, 14, 16].  
Before conducting the probabilistic record linkage, the two databases were standardized using 
Statistical Package for the Social Sciences (SPSS, version 15), so that all corresponding variables used in 
the process had the same format, length and coding. For the linkage process, the records were compared 
based on patient’s full name and date of birth using the open source software OpenRecLink (version 2.9). 
A multi-step procedure was employed and clerical review of matches, based on mother’s name and 
address, was carried out to improve both sensitivity and specificity.  
After finalizing the record linkage process for manuscripts one (trends) and two (risk), the 
following exclusion criteria, which have been used in previous studies, were employed: cancer cases 
which occurred 60 months or earlier before AIDS diagnosis (n = 86), cases of basal cell skin cancer (n = 
173); and in situ cancer cases (n = 238). These cases were removed from all analyses. Therefore, for these 
manuscripts 2,074 cancer cases were assessed in 2,000 people with AIDS (74 patients had two primary 
site tumors). As for the manuscript on survival, further exclusion criteria allowing for complete follow up 
of patients were applied, and the final sample comprised 1,314 cancer cases in 1,294 people with AIDS.  
Crude rates were calculated by dividing the number of cases by the respective population at risk, 
according to sex. Age-standardized incidence rates were calculated, based on the world population 
proposed by SEGI (1960) and modified by DOLL (1976) [17, 18].  
3.1. Trends in the incidence 
The trend analyses were conducted using Joinpoint software. Joinpoint estimates the annual 
percent change (APC) and their respective 95% confidence intervals (95% CI) using an exponential 
distribution. The software identifies shifts in trends, breaking the whole period into subsets and 
calculating the APC for each resulting period [19]. In the present study, the three-year moving average of 
the age-standardized incidence rates was used to estimate the APC for AIDS-defining and non-AIDS-
defining cancers overall and for the most incident cancer site/type, namely: Kaposi sarcoma, non-
Hodgkin lymphoma, anal, lung and colorectal cancers, in men; Kaposi sarcoma, non-Hodgkin lymphoma, 
cervical, breast and colorectal cancers in women. 
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3.2. Risk for cancer 
The comparison of the risk for cancer across populations (AIDS versus general population) was 
performed using the standardized incidence ratio (SIR), which is the ratio of expected and observed cases, 
and respective 95% confidence intervals. To obtain the expected number of cases in the AIDS population 
during the period of 1997-2012, age-specific rates in the general population, which were provided by the 
“Population-based Cancer Registry of São Paulo”, were considered. The SIRs were calculated according 
to sex and site/type of cancer. These analyses were conducted using the package Epidemiological tools 
(Epitools) with the software R. 
3.3. Survival after cancer diagnosis 
The survival analyses were possible because the “Population-based Cancer Registry of São 
Paulo” has access to the mortality database of the city of São Paulo (Programa de Aprimoramento das 
Informações de Mortalidade no Município de São Paulo - PRO-AIM/ Program for Improvement of Death 
Information). In these analyses the cases diagnosed between 1997 and 2009 and followed up for at least 
five years until the outcome of interest (death from any cause) was observed or until the end of the 
observation period was reached (31st of December 2014) whichever occurred earlier, were included. For 
those patients who survived beyond this threshold, time was right-censored. 
Controls from the general population (without AIDS) were selected to allow for comparison. The 
survival analyses were conducted using Kaplan Meier methods and Cox proportional hazards models, 
stratified by matching variables and adjusted for age (in years). These analyses were stratified by cancer 
site/type and performed using Stata (version 13). 
3.4. Ethics 
Ethical clearance was obtained from the Ethics Review Board at School Public Health, University 
of São Paulo (opinion number 686.849), the Municipal Health Secretariat of São Paulo (opinion number 
703.467) and the University of Munich (opinion number 233-15) prior to study initiation.  
All database management and record linkage were conducted by the main investigator in a 
password-protected computer which was not connected to any network. After selection of true matches, 
identification information was deleted to ensure data privacy. 
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4. Results
A multi-step record linkage process was conducted with the final database containing 2,571 
matches (Figure 1). As described in the methods, some cancer cases were removed before further 
analyses. For this thesis the descriptive analysis comprises 2,074 cancer cases, diagnosed in 2,000 people 
with AIDS (seventy-four people had two primary site tumors).  
Figure 1 - Probabilistic record linkage between the “Population-based Cancer Registry of São Paulo” and 
Information System on Disease Notification database (SINAN). 
The majority were male (1,461; 73.0%), white (1,111; 55.6%) and aged 30-49 years old at cancer 
diagnosis (1,257; 62.9%). About half of them (974; 48.7%) had five to eleven years of schooling. 
Heterosexual (674; 33.7%) and homosexual (447; 22.4%) practices were the most frequently stated 
categories of exposure to HIV. 
In the AIDS population, most cancers (1,057 out of 2,074 cancers; 51.0%) were classified as non-
AIDS defining, corresponding to 56.7% of cancers in women (n = 320 out of 564). In men, AIDS-
defining cancers were slightly more frequent than non-AIDS defining cancers, adding up to 51.2% (n = 
773) of all 1,510 cancer cases. The five most incident cancer sites/types among men with AIDS were
Kaposi sarcoma (469; 31.1%), non-Hodgkin lymphoma (304; 20.1%), anal cancer (63; 4.2%), colorectal 
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cancer (59; 3.9%) and lung cancer (54, 3.6%). Cervical cancer (114; 20.2%), non-Hodgkin lymphoma 
(96; 17.0%), breast cancer (72; 12.8%), Kaposi sarcoma (34; 6.0%) and colorectal cancer (19; 3.4%) were 
the most frequently found cancer sites/types in women with AIDS. 
4.1. Trends in the incidence 
The trend analyses in men with AIDS, revealed a statistically significant decline in general for 
AIDS-defining cancers (APC = -14.1%/year), but also in particular for Kaposi sarcoma (APC = 
-16.2%/year) and non-Hodgkin lymphoma (APC = -11.9%/year). Conversely, all non-AIDS-defining
cancers decreased (APC = -9.7%/year) until the mid-2000’s, when a significantly increasing trend could 
be detected (APC = 7.4%/year). When considering men with AIDS, the incidence of anal and lung 
cancers have significantly increased (by 24.6% and 15.9%, respectively), whereas the incidence of 
colorectal cancer remained stable. In the general male population had significant declines in incidence of 
non-Hodgkin lymphoma (-2.8%/year), colorectal (-1.3%/year), lung (-7.6%/year) and anal (-5.9%/year) 
cancers. 
For women with AIDS significant declining trends were found in the incidence of AIDS-defining 
cancers (APC = -15.6%/year) in general, and for Kaposi sarcoma (APC = -26.7%/year), non-Hodgkin 
lymphoma (APC = -15.8%/year), cervical cancer (APC = -12.8%/year) and breast cancer (APC = 
-10.1%/year) in particular. The incidence of colorectal cancer, on the other hand remained stable
throughout the study period. Similarly, the decline was statistically significant (APC = -15.8%/year) for 
all non-AIDS-defining cancers. A similar declining pattern in the general female population was 
identified for all cancers analyzed. 
4.2. Risk for cancer 
The overall risk of AIDS-defining cancers and non-AIDS-defining cancers among males with 
AIDS were significantly higher than among the male general population (SIRM = 27.74 and 1.87 
respectively) than among females with AIDS compared to the female general population (SIRF = 8.71 and 
1.44 respectively). Most virus-related non-AIDS-defining cancers occurred at elevated rates among 
people with AIDS: anal cancer (SIRM = 33.02; SIRF = 11.21), liver cancer (SIRM = 4.35; SIRF = 4.84), 
vulvar and vaginal cancer (SIRF = 6.78), Hodgkin lymphoma (SIRM = 5.84; SIRF = 2.71), among others. 
Cancers of the trachea and lung (SIRM = 2.24; SIRF = 2.60), central nervous system (SIRM = 1.92; SIRF = 
3.48), and eye in men (SIRM = 5.28) were also more frequently found in people with AIDS. 
In contrast to this, the estimated standardized incidence rates of cancers of the breast, prostate, 
bladder and esophagus did not differ across populations. Only thyroid cancer occurred at lower rates in 
both men and women with AIDS in comparison to the general population (SIRM = 0.50; SIRF = 0.48).  
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4.3. Survival after cancer diagnosis 
The overall five-year survival in people with AIDS after cancer diagnosis was 49.4% (versus 
72.7% in matched people without AIDS) and the hazard ratio was 2.64 (95% CI = 2.39-2.91). More 
specifically, the hazard ratios were 2.93 for AIDS-defining (95% CI = 2.49-3.45) and 2.51 (95% CI = 
2.21-2.84) for non- AIDS-defining cancers. 
Among people with AIDS, the poorest survival probabilities were seen for cancers of the trachea 
and lung (10.5%) and liver (11.1%), as well as for leukemia (14.3%). Conversely, the highest survival 
probabilities were found for cancers of the thyroid (86.7%), eye (85.7%), vulva and vagina (77.8%) and 
nonmelanoma skin cancer (70.6%). 
With a few exceptions, the type/site-specific analyses revealed a significantly lower survival 
probability after cancer diagnosis in people with AIDS when compared to the general population. 
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5. Discussion
This thesis described the cancer spectrum in the era of availability of the highly active 
antiretroviral therapy among people with AIDS living in São Paulo, the largest city in Brazil and in South 
America. The incidence of AIDS-defining cancers has shown a pronounced reduction throughout the 
study period. Nevertheless, people with AIDS remain at higher risk of developing certain malignancies, 
both AIDS-defining and non-AIDS-defining. For those who developed cancer, the survival probability 
after diagnosis is generally impaired when compared to that of the general population. 
The findings presented by this study are closer to scenarios of industrialized countries, as 
compared to other low- and middle-income countries, probably due to two aspects: the characteristics of 
the AIDS epidemic and the access to antiretroviral therapy. In São Paulo, AIDS is still more prevalent in 
men, with homosexual exposure to HIV representing an important mode of transmission. However, the 
male to female ratio of newly diagnosed cases has dramatically fallen from 26:1 in 1985 to 2:1 in 2011 
[20]. In the United States and Western European countries the HIV-infected populations have similar 
features, whereas in sub-Saharan Africa, women are disproportionally more affected by AIDS and 
heterosexual infection is predominant [21]. Furthermore, antiretroviral therapy has been provided free of 
cost in Brazil to all patients in need since 1996. Brazil was the first developing country to promote such a 
low barrier policy. Thus, regardless of a patient’s economic condition, treatment is universal. More 
recently, the country updated its treatment guidelines and since the end of 2013 the Brazilian Ministry of 
Health strongly recommends immediate initiation of antiretroviral therapy regardless of CD4 count [22]. 
Only a few countries worldwide have adopted a similar measure, despite being the current 
recommendation of the World Health Organization since 2015 [23]. 
Cancer burden among people with AIDS in São Paulo was similar to that previously described in 
other areas located in high-income countries [12, 24, 25]. The majority of virus-related cancers occurred 
at elevated rates. Apart from cancers of the tongue and penis, the human papilloma virus-related cancers 
(anus, cervix, tonsil and oropharynx, vulva and vagina) were more frequently found in people with AIDS. 
Liver cancer, which is related to the hepatitis B and C viruses, as well as cancer of the nasopharynx and 
Hodgkin lymphoma, both Epstein-Barr-virus-related, also occurred at higher rates. These virus-related 
cancers accounted for an important share of excessive cases in people with AIDS, as coinfection with 
oncogenic viruses disproportionally affects this population [24-27]. Tobacco-associated malignancies, 
especially cancer of the trachea and lung, were also more frequent in this population.  
As for survival after cancer diagnosis, the results revealed poorer probabilities among people with 
AIDS which could be a result of several factors, including faster disease progression, late diagnosis, 
disparities of treatment uptake in comparison to the general population, lack of specific treatment 
guidelines for this population and death from other causes [28-31].  
Brazil has been an important part of the global history of HIV/AIDS, having developed over the 
years a national Sexually Transmitted Diseases/AIDS program that is considered by many as an 
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inspiration for the developing world. This study underscores the effects of the Brazilian policy of 
universal access to antiretroviral treatment in the incidence of AIDS-defining cancers, but also reveals the 
need of measures to address emerging non-AIDS-defining cancers, including the intensification of anti-
tobacco strategies aimed at this specific population. Since Brazil already offers antiretroviral treatment to 
all HIV-infected regardless of disease stage, early diagnosis of HIV infection is also an important part of 
cancer prevention in this population. A recent study revealed that immediate initiation of antiretroviral 
therapy significantly reduces the risk of cancer [32].  
As the life expectancy of HIV-infected people has dramatically improved since the advent of the 
highly active antiretroviral therapy and is now comparable to that of the general population, the HIV-
infected population has dramatically enlarged and aged over the years. Therefore, more people are at risk 
of developing cancer and the healthcare system should be ready to follow up to offer adapted health care 
packages for this particular population. Specific prevention and screening strategies might also contribute 
to the management of cancer in this population and should be investigated further. 
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Original research article
Trends in the incidence of AIDS-defining
and non-AIDS-defining cancers in people
living with AIDS: a population-based study
from Sa˜o Paulo, Brazil
Luana F Tanaka1,2,3, Maria do Rosa´rio DO Latorre2,3,
Eliana B Gutierrez4, Christian Heumann5, Karl-Heinz Herbinger6
and Guenter Froeschl1,6
Abstract
People living with AIDS are at increased risk of developing certain cancers. Since the introduction of the highly active
antiretroviral therapy (HAART), the incidence of AIDS-defining cancers (ADCs) has decreased in high-income countries.
The objective of this study was to analyse trends in ADCs and non-AIDS-defining cancers (NADCs) in HIV-positive
people with a diagnosis of AIDS, in comparison to the general population, in Sa˜o Paulo, Brazil. A probabilistic record
linkage between the ‘Population-based Cancer Registry of Sa˜o Paulo’ and the AIDS notification database (SINAN) was
conducted. Cancer trends were assessed by annual per cent change (APC). In people with AIDS, 2074 cancers were
diagnosed. Among men with AIDS, the most frequent cancer was Kaposi’s sarcoma (469; 31.1%), followed by non-
Hodgkin lymphoma (NHL; 304; 20.1%). A decline was seen for ADCs (APC¼14.1%). All NADCs have increased
(APC¼ 7.4%/year) significantly since the mid-2000s driven by the significant upward trends of anal (APC¼ 24.6%/year)
and lung cancers (APC¼ 15.9%/year). In contrast, in men from the general population, decreasing trends were observed
for these cancers. For women with AIDS, the most frequent cancer was cervical (114; 20.2%), followed by NHL (96;
17.0%). Significant declining trends were seen for both ADCs (APC¼15.6%/year) and all NADCs (APC¼15.8%/
year), a comparable pattern to that found for the general female population. Trends in cancers among people with AIDS
in Sa˜o Paulo showed similar patterns to those found in developed countries. Although ADCs have significantly decreased,
probably due to the introduction of HAART, NADCs in men have shown an opposite upward trend.
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Introduction
Several studies have shown an increased risk for cancer
among people living with HIV/AIDS (PLWHA);
however, the risks have changed over time. Since the intro-
duction of the highly active antiretroviral therapy
(HAART), some countries have documented signiﬁcant
declines in AIDS-deﬁning cancers (ADCs), namely
Kaposi’s sarcoma (KS), non-Hodgkin lymphoma
(NHL) and cervical cancer (CC). In contrast to this,
increasing trends in non-AIDS-deﬁning cancers
(NADCs) were found in many recent studies.1–5 Most of
the studies assessing cancer burden in PLWHA have been
conducted in developed countries, such as the United
States (US), Spain and Italy, where population-based
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cancer and AIDS registries coexist. Unfortunately, in
many countries, both at high- and or middle-income
levels, such studies are not feasible, due to the lack of
population-based registries, or due to the inability of con-
ducting record linkage because of anonymized records,
poor database quality or intermittent data collection,
among other constraints.
In Brazil, AIDS notiﬁcation became mandatory in
1986 and cases diagnosed before that time were rec-
orded retrospectively. The state of Sa˜o Paulo has
played a crucial role in the AIDS epidemic, having
launched the ﬁrst AIDS programme in the country,
providing treatment free of cost.6 Sa˜o Paulo city has
the highest percentage (12.6%) of all AIDS cases diag-
nosed nationally.7 The city also has a population-based
cancer registry, which covers the largest population in
Brazil, and has uninterruptedly collected data on cancer
incidence since 1997.
The present study analysed the trends in incidence
of cancers in residents of Sa˜o Paulo with HIV between
1997 and 2012, in comparison to the general population.
Methods
A total of 87,109 AIDS cases were diagnosed in HIV-
positive persons aged 13 years in Sa˜o Paulo from 1980
to 2013.8 Between 1997 and 2012, the ‘Population-based
Cancer Registry of Sa˜o Paulo’ (PBCR-SP) registered
628,161 cancers (496,276 invasive) among Sa˜o Paulo
residents.
A probabilistic record linkage was conducted between
the PBCR-SP (1997–2012) and the AIDS notiﬁcation
database SINAN (Sistema de Informac¸o˜es de Agravos
de Notiﬁcac¸a˜o/Information System on Disease
Notiﬁcation) (1980–2013) containing AIDS cases. The
Brazilian Ministry of Health preferably uses the AIDS
case deﬁnition of the Centers for Disease Control and
Prevention and alternatively the deﬁnition of Rio de
Janeiro/Caracas.9 Both registries cover the same terri-
tory: the city of Sa˜o Paulo, which according to the
2010 census, comprises an area of 1521 km2 and is
home to 11,253,503 inhabitants (99.1% urban), corres-
ponding to almost 6% of the Brazilian population. Its
current human development index is 0.805.10
A probabilistic record linkage was conducted, in a
multi-step process, using diﬀerent blocking strategies.
Soundex, which is the phonetic algorithm for indexing
names by sound, was used in place of names for block-
ing. The blocking strategies contained a combination of
soundex of the ﬁrst name, soundex of the last name,
decade of birth and sex. Full name and date of birth
were used for calculating the weighted scores. Clerical
review based on name, date of birth, mother’s name
and address, when available, was carried out in all
steps to improve record linkage sensitivity. This process
was conducted using the open source software
OpenRecLink (version 2.9). After the identiﬁcation of
true matches, patients were excluded from the analysis
if they had a cancer diagnosis 60 months or more prior
to their AIDS diagnosis.
Cancers were grouped into two major categories:
ADCs (KS, NHL and CC) and NADCs (all other can-
cers). The annual AIDS population according to
gender and age group was estimated as the diﬀerence
between cumulative cases and cumulative deaths per
year.
The crude incidence rates were calculated according to
gender, dividing the number of incident cases by the esti-
mated AIDS population in a given year and presented as
rates per 100,000 persons. Crude rates were also calcu-
lated according to the following age groups: 20–29, 30–39,
40–49, 50–59, 60–69 years. As for the general population,
the denominator for rates was the resident population
of Sa˜o Paulo, as provided by the Brazilian Institute
of Geography and Statistics.10 Age-standardized rates
(ASRs) by sex were calculated using the direct method
based on the world population, as proposed by SEGI and
modiﬁed by Doll and Waterhouse.11
In the descriptive analyses, persons with multiple
cancer diagnoses were only included once (considering
the ﬁrst cancer). To assess trends in ADCs, NADCs
and most incident cancers (anal, colorectal and lung
cancers in men; breast and colorectal cancers in
women) in the population with AIDS, the three-year
moving average of the ASR was calculated.
Subsequently, the annual per cent change (APC) was
estimated, as follows: APC ¼ ½exp year
  1  100,
and its respective 95% conﬁdence intervals with expo-
nentially transformed values using the Joinpoint soft-
ware (version 4.2.0.2). Data from the PBCR-SP were
analysed to assess trends in cancer incidence in the gen-
eral population. The series of the PBCR-SP started in
1997. Since its trends are greatly aﬀected by the AIDS
epidemic, no speciﬁc trend analysis for the general
population was conducted for KS.
To compare risk for cancer within age groups, the
ratio between crude age-speciﬁc rates of the oldest age
group (60–69 years) and the youngest (20–29 years) was
calculated. All statistical analyses were stratiﬁed by sex.
This research obtained ethical clearance from the
Ethics Review Board at the School Public Health,
University of Sa˜o Paulo (686.849), from the Municipal
Health Secretariat of Sa˜o Paulo (703.467) and from the
University of Munich (233.15). After record linkage, the
database was anonymized to ensure data privacy.
Results
Table 1 displays the main characteristics of all AIDS
cases registered in Sa˜o Paulo from 1980 to 2013.
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The majority of cases were men (72.8%), aged 20–49
years (88.5%) at AIDS diagnosis. The estimated
number of persons living with AIDS increased substan-
tially from 13,895 (of which 76.1% are males) in 1997
to 44,741 (of which 69.0% are males) in 2012. Young
males (20–49 years) accounted for over 60% of the
AIDS population at risk of cancer (data not shown).
Of all 496,276 invasive cancers diagnosed between
1997 and 2012, 2074 cancers occurred in 2000 persons
with AIDS. Seventy-four persons were diagnosed with
two primary site tumours, thus, the descriptive statistics
shown in Table 2 was based on 2000 persons. The
majority were male (1461; 73.0%), white (1111;
55.6%) and aged 30–49 years old at cancer diagnosis
(1257; 62.9%). Heterosexual (674; 33.7%) and homo-
sexual (447; 22.4%) practices were the most frequent
stated categories of exposure to HIV.
Table 3 presents the number of cases and trend ana-
lyses of ADCs, NADCs, and most incident cancers in
men and women both with AIDS and from the general
population; in these analyses all 2074 cancers were con-
sidered. Most cancers (51.0%; 1057 out of 2074
cancers) in the AIDS population were classiﬁed as
NADCs, corresponding to 56.7% cancers in women
(n¼ 320). In men, ADCs were slightly more frequent
than NADCs, representing 51.2% (n¼ 773) of all 1510
male cases. The ﬁve most incident cancers among men
with AIDS were KS (469; 31.1%), NHL (304; 20.1%),
anal cancer (63; 4.2%), colorectal cancer (59; 3.9%) and
lung cancer (54, 3.6%). In the general male popula-
tion, the most frequent cancer sites were prostate
(23.4%), colon and rectum (9.5%), lung (7.2%), stomach
(6.5%) and skin non-melanoma (6.1%) (data not shown).
In women with AIDS, CC (114; 20.2%), NHL
(96; 17.0%), breast cancer (72; 12.8%), KS (34; 6.0%)
and colorectal cancer (19; 3.4%) were the most incident
cancers. In contrast, among women from the general
population, breast (25.6%), colon and rectum (8.9%),
Table 1. Socio-demographic characteristics of people diagnosed with AIDS, according to
gender. Sa˜o Paulo, 1980–2013.
Total Male Female
n % n % n %
Race/ethnicity
White 21,935 25.2 15,360 24.2 6575 27.8
Black 4292 4.9 2715 4.3 1577 6.7
Asian 303 0.3 214 0.3 89 0.4
Pardoa 10,079 11.6 6484 10.2 3595 15.2
Indigenous 64 0.1 48 0.1 16 0.1
Unknown 50,436 57.9 38,616 60.9 11,820 49.9
Age at AIDS diagnosis (years)
13–19 1453 1.7 963 1.5 490 2.1
20–29 22,818 26.2 16,044 25.3 6774 28.6
30–39 34,892 40.1 26,132 41.2 8760 37.0
40–49 18,944 21.7 13,964 22.0 4980 21.0
50–59 6548 7.5 4621 7.3 1927 8.1
60–69 1853 2.1 1258 2.0 595 2.5
70 423 0.5 311 0.5 112 0.5
Unknown 178 0.2 144 0.2 34 0.1
HIV exposure category
Homosexual men 17,589 20.2 17,589 27.7 NA NA
Bisexual 6001 6.9 5977 9.4 24 0.1
Heterosexual 31,550 36.2 14,832 23.4 16,718 70.6
Intravenous drug user 13,643 15.7 11,256 17.7 2387 10.1
Other 595 0.7 402 0.6 193 0.8
Unknown 17,731 20.4 13,381 21.1 4350 18.4
Total 87,109 100 63,437 100 23,672 100
NA: not applicable.
aPardo refers to multiracial persons of African ancestry.
Source: Epidemiological surveillance on STDs/AIDS, Municipal Department of Health, Sa˜o Paulo, Brazil.
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thyroid (7.5%), cervix (5.2%) and skin non-melanoma
(5.2%) were the most frequent cancer sites (data not
shown).
As for the trend analyses in men with AIDS, a statis-
tically signiﬁcant decline was seen in general for ADCs
(APC¼14.1%/year), but also in particular for KS
(APC¼16.2%/year) and NHL (APC¼11.9%/year).
In contrast to this, all NADCs decreased (APC¼
9.7%/year) until the mid-2000s, when it started
to increase (APC¼ 7.4%/year). Incidence of anal and
lung cancer have signiﬁcantly increased by 24.6
and 15.9%, respectively, whereas colorectal cancer
remained stable. In the general male population, NHL,
colorectal, lung and anal cancers had signiﬁcant declines
in incidence of 2.8, 1.3, 7.6, 5.9%/year, respect-
ively (Figure 1(a) to (d)).
Among women with AIDS, a statistically signiﬁcant
decline was seen in general for ADCs (APC¼15.6%/
year), and in particular for KS (APC¼26.7%/year),
NHL (APC¼15.8%/year), CC (APC¼12.8%/
year) and breast cancer (APC¼10.1%/year) in par-
ticular. In contrast to this, the incidence of colorectal
cancer remained stable. Additionally, also for all
NADCs (APC¼15.8%/year), the decline was signiﬁ-
cant. Declining trends in all cancers analysed were
found for women from the general population.
Table 2. Socio-demographic characteristics of 2000 people with AIDS and cancer, according
to gender. Sa˜o Paulo, 1997–2012.
Total Male Female
n % n % n %
Race/ethnicity
White 1111 55.6 860 58.9 251 46.6
Black 143 7.2 84 5.7 59 10.9
Asian 14 0.7 10 0.7 4 0.7
Pardoa 255 12.8 159 10.9 96 17.8
Unknown 477 23.9 348 23.8 129 23.9
Age at AIDS diagnosis (years)
13–19 16 0.8 9 0.6 7 1.3
20–29 348 17.4 241 16.5 107 19.9
30–39 733 36.7 534 36.6 199 36.9
40–49 528 26.4 397 27.2 131 24.3
50–59 277 13.9 210 14.4 67 12.4
60–69 82 4.1 55 3.8 27 5.0
70 16 0.8 15 1.0 1 0.2
Age at cancer diagnosis (years)
13–19 8 0.4 6 0.4 2 0.4
20–29 225 11.3 163 11.2 62 11.5
30–39 650 32.5 467 32.0 183 34.0
40–49 607 30.4 438 30.0 169 31.4
50–59 348 17.4 271 18.5 77 14.3
60–69 135 6.8 95 6.5 40 7.4
70 27 1.4 21 1.4 6 1.1
HIV exposure category
Homosexual men 447 22.4 447 30.6 NA NA
Bisexual 179 9.0 179 12.3 – –
Heterosexual 674 33.7 313 21.4 361 67.0
Intravenous drug user 145 7.3 105 7.2 40 7.4
Other 10 0.5 4 0.3 6 1.1
Unknown 545 27.3 413 28.3 132 24.5
Total 2000 100 1461 100 539 100
NA: not applicable.
aPardo refers to multiracial persons of African ancestry.
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The analysis of crude rates stratiﬁed by age group
revealed that the risk for all ADCs (KS, NHL and CC)
increased with age (Figure 2(a) and (b)). Risk for all
NADCs among persons with AIDS was 38.3-fold in
men and 35.6-fold in women, when comparing the oldest
(60–69 years) to the youngest age group (20–29 years).
Discussion
This is the ﬁrst study in Brazil estimating the incidence
of cancer in patients with AIDS at a population level.
Our results reveal a high and changing cancer burden in
this population, as found in similar studies conducted
in North America and Europe, as well as a multicentre
cohort study performed in Rio de Janeiro (Brazil) and
Nashville (US).2,4,5,12,13
Although approximately half of cancers identiﬁed in
our study were classiﬁed as ADCs, their incidences have
dramatically declined in Sa˜o Paulo, but remain at high
rates when compared to the general population.
Declining trends in ADCs have been documented in sev-
eral studies, with one of themost probable contributors to
this being the introduction of HAART in 1996.2,5
Treatment with HAART, if timely, alters the course of
HIV infection by preventing or reversing profound
immunosuppression, and thereby, decreasing susceptibil-
ity of developing AIDS-deﬁning illnesses, including
ADCs.14,15 Despite eﬀorts to scale up HIV testing and
early diagnosis, late entries to HIV care are still very fre-
quent worldwide and could prevent further reduction in
ADCs burden.16,17 A study conducted in Brazil revealed
that between 2003 and 2006, 43.6% of persons aged 15
and older diagnosed with AIDS entered HIV care late,
either having CD4þ cell counts 200 cells/mm3, an
AIDS-deﬁning illness at the initial examination or
having died within the ﬁrst 20 days of entry.18 In these
cases, delayed introduction of HAART could be less
eﬀective in improving the immune system and its ability
to control oncogenic viruses, such as Epstein–Barr virus
(risk factor for NHL) and human herpes virus 8 (asso-
ciated with KS), increasing the overall risk for ADCs.
On the other hand, since 2013, the Brazilian
Ministry of Health encourages the immediate initiation
of antiretroviral therapy among all individuals diag-
nosed with HIV infection, regardless of CD4þ cell
counts.19 This measure could lead to further declines
in ADCs, by preventing persons diagnosed with HIV
only from developing AIDS and its deﬁning illnesses.
Steep reduction (APC¼15.8% in women; 11.9%
in men) in NHL in the AIDS population could have
Table 3. Trends in 2074 cancer cases found among 2000 people with AIDS and cancer and people from general population,
according to sex. Sa˜o Paulo, 1997–2012.
Persons with AIDS General population
n APC 95% CI p n APC 95% CI p
Malea
All AIDS-defining cancers 773 14.1 16.6; 11.6 <0.01 NA NA NA NA
Kaposi sarcoma 469 16.2 18.8; 13.4 <0.01 NA NA NA NA
Non-Hodgkin lymphoma 304 11.9 15.5; 8.2 <0.01 7719 2.8 3.5; 2.1 <0.01
All non-AIDS-defining cancers (1997–2005)b 361 9.7 12.2; 7.1 <0.01 NA NA NA NA
All non-AIDS-defining cancers (2005–2012) 376 7.4 3.6; 11.4 <0.01 NA NA NA NA
Anal cancerc 63 24.6 16.0; 33.9 <0.01 616 5.9 10.1; 1.5 <0.01
Colorectal cancer 59 3.9 11.5; 4.3 0.30 22,565 1.3 2.1; 0.5 <0.01
Lung cancer 54 15.9 6.9; 25.7 <0.01 17,082 7.6 8.3; 6.9 <0.01
Femaled
All AIDS-defining cancers 244 15.6 18.8; 12.3 <0.01 NA NA NA NA
Cervical cancer 114 12.8 16.3; 9.2 <0.01 14,765 8.2 9.1; 7.3 <0.01
Non-Hodgkin lymphoma 96 15.8 20.0; 11.4 <0.01 7220 2.4 3.0; 1.7 <0.01
Kaposi sarcoma 34 26.7 34.7; 17.7 <0.01 NA NA NA NA
All non-AIDS-defining cancers 320 15.8 20.0; 11.3 <0.01 NA NA NA NA
Breast cancer 72 10.1 19.1; 0.2 <0.01 72,134 1.8 2.5; 1.1 <0.01
Colorectal cancer 19 1.9 10.3; 15.8 0.70 24,975 1.5 2.3; 0.7 <0.01
APC: annual per cent change; CI: confidence interval; NA: not applicable.
aCancer cases add up to 1510 in men with AIDS.
bSegment provided by Joinpoint.
c2002 onwards.
dCancer cases add up to 564 in the women with AIDS.
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Figure 1. (a) Age standardized incidence rates of AIDS-defining and non-AIDS-defining cancers in the AIDS population according to
gender. Sa˜o Paulo, 1997–2012. Rates are presented based on three-year moving average and displayed on a logarithmic scale. (b) Age
standardized incidence rates of Kaposi’s sarcoma in the AIDS population according to gender. Sa˜o Paulo, 1997–2012. Rates are
presented based on three-year moving average. (c) Age standardized incidence rates of non-Hodgkin lymphoma in the AIDS popu-
lation and in the general population according to gender. Sa˜o Paulo, 1997–2012. Rates are presented based on three-year moving
average and displayed on a logarithmic scale. (d) Age standardized incidence rates of cervical cancer in the AIDS population and in the
general population. Sa˜o Paulo, 1997–2012. Rates are presented based on three-year moving average and displayed on a logarithmic
scale.
Figure 2. (a) Crude incidence rates for AIDS-defining cancers, non-AIDS-defining cancers, Kaposi’s sarcoma and non-Hodgkin
lymphoma in men with AIDS according to age group. Sao Paulo, 1997–2012. Rates are displayed on a logarithmic scale. (b) Crude
incidence rates for AIDS-defining cancers, non-AIDS-defining cancers, Kaposi’s sarcoma, non-Hodgkin lymphoma and cervical cancer
in women with AIDS according to age group. Sao Paulo, 1997–2012. Rates are displayed on a logarithmic scale.
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contributed to declining trends at the general popula-
tion level (APC¼2.4% in women; 2.8% in men),
as they account for 4% of all cases. Similar declining
patterns for CC were identiﬁed in women with AIDS
and women from the general population. In both cases,
the propagation of Pap smear screening may have con-
tributed to this epidemiological pattern as the test can
identify cervical lesions before they evolve to CC.
In Sa˜o Paulo, over 90% of female inhabitants belong-
ing to the screening target group reported to have had
at least one Pap smear in the last three years.20
Conversely, NADCs have become progressively cru-
cial over the years. In both men and women, incidence
of NADCs surpassed ADCs in the mid-2000s, but in
men, the incidence has been particularly increasing
since 2005, driven by lung and anal cancers. Other
NADCs, such as female breast and colorectal cancers
in the AIDS population follow the pattern of the gen-
eral population. In Sa˜o Paulo, coverage of the breast
cancer screening programme is about 80%.20
The increasing trend in lung cancer among men
is not surprising. According to the Brazilian Ministry
of Health, the prevalence of smoking among PLWHA
ranges from 50 to 70%,19 which is considerably higher
than that of the general population (14.9% in 2013 in
Sa˜o Paulo).20 Recent data from the US revealed that
lung cancer has decreased more rapidly in PLWHA
than in the general population, though the authors
believe that this might result from a faster decline in
smoking prevalence in the ﬁrst group.2 In Sa˜o Paulo
there are no data suggesting changes in smoking
prevalence in this population. In line with our results,
lung cancer in PLWHA in Italy has increased in the
post-HAART era when compared to the pre-HAART
era.5 Previous studies have shown that higher inci-
dence of lung cancer in this population is mainly
attributable to tobacco smoking rather than other
cofactors.21 There is an ongoing debate on the eﬀect-
iveness of screening for lung cancer, and until there is
enough evidence to adopt it, management of this
malignancy must focus on strategies to promote
tobacco cessation.
As for anal cancer in the male population with
AIDS, there is a clear increasing trend since 2002,
which is contrary to the drop observed in the general
population. Similar results have been reported in Italy
and the US, though in the US increasing trends in
anal cancer in the AIDS population have been identi-
ﬁed as driving the upward trend in the general popu-
lation.2,5 Anal cancer has been strongly linked to
persistent HPV infection and tobacco smoking,22 and
the risk among PLWHA is as high as 37-fold when
compared to the general population.23 A multicentre
study in Brazil of 445 HIV-positive men, found a
65.6% prevalence of HPV DNA in anal swabs, with
40.7% detected as oncogenic HPV strains.24 In an
eﬀort towards early detection of anal cancer and its
precursor lesions in PLWHA, the Brazilian Ministry
of Health has recommended since 2013 annual anal
Pap smears for patients who have receptive anal inter-
course, HPV infection history, or abnormal vulvar or
cervical histology.19 This strategy could lead to
changes in anal cancer burden in the high-risk popu-
lation in the future.25
Our ﬁndings are closer to that of industrialized
countries, probably due to two aspects: the charac-
teristics of the AIDS epidemic and the access to anti-
retroviral therapy. In Sa˜o Paulo, AIDS is still more
prevalent in men, with homosexual exposure to HIV
representing an important mode of transmission.
However, male-to-female ratio of AIDS cases has dra-
matically fallen from 26:1 in 1985 to 2:1 in 2011.26
In the US and Western European countries, the popu-
lations of PLWHA have similar features, whereas in
sub-Saharan Africa, women are disproportionally
more aﬀected by AIDS and heterosexual infection is
predominant.27 Concerning antiretroviral therapy, pro-
vided in Brazil since 1996, treatment is free of cost
to all patients in need. Thus, regardless of a patient’s
economic condition, treatment is universal.28
The analysis of crude rates by age groups highlights
that as patients age the risk for cancer increases, but the
risk is more pronounced for NADCs. Incidence of
NADCs peaks at older ages, a pattern observed for
most cancers in the general population. Polesel et al.,5
when assessing NADCs in PLWHA in Italy, concluded
that the strong changes in crude rates were driven by
the ageing of the AIDS population.5
As for limitations, this study is restricted to the
AIDS population and does not examine HIV-only
patients. Even though the city of Sa˜o Paulo occasion-
ally provided notices regarding HIV infection, notiﬁca-
tion has only recently become mandatory (in June
2014). Thus, data for HIV-only cases for the study
period are not precise and was therefore not analysed.
Information on clinical data, including CD4þ cell
count, viral load and antiretroviral therapy was not
assessed because it is not routinely collected by the
AIDS registry (SINAN).
The shorter coverage period of the PBCR-SP has
limited our analysis to the post-HAART era. It would
have been valuable to understand the risk for cancer in
this population before HAART became fully available.
Three main sources of cancer underestimation may
have occurred in our study. First, this study relies
on probabilistic record linkage itself. This method is
not error free and might have failed in the identiﬁcation
of some of those PLWHA who had cancer in the study
period. To minimize this issue and improve our data
matching sensitivity, a multi-step process was carried
1196 International Journal of STD & AIDS 28(12)
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out and clerical review was employed. Even so, some
degree of underestimation may have occurred.
Nevertheless, this strategy has also been employed to
estimate cancer incidence in PLWHA in other countries
and is the primary source of population-based data.
A second factor that could result in cancer under-
estimation is outmigration. Residents of Sa˜o Paulo who
were diagnosed with AIDS and outmigrated later could
not be captured by our database linkage. There are no
data on the percentage of outmigration among AIDS
patients, but available information from a report
assessing incident cancer cases registered in Sa˜o Paulo
revealed that 4% of deaths were registered outside the
municipality (outmigration).29 If one assumes that the
percentage of AIDS cases that moved to other munici-
palities is similar and that not all of them would
develop cancer, then outmigration would not greatly
interfere with our ﬁndings.
Lastly, PLWHA who are unaware of their status
may have been misclassiﬁed in our study, and therefore
failed to contribute to the cancer burden in persons
with AIDS. Nevertheless, this is to be expected in stu-
dies, which are based on passive case ﬁnding.
Despite the aforementioned constraints, the present
study provides valuable population-based information
from a developing country. The current body of know-
ledge is composed mainly of research conducted in
developed countries with this study providing aggre-
gated data from a developing country known for its
particular plan to ﬁght AIDS. Our ﬁndings highlight
a marked decrease in ADCs for both genders and a
recent increase in NADCs among men, mainly driven
by lung and anal cancers. Stratiﬁcation by gender was
important to identify diﬀerent patterns in cancer trends.
This suggests that exposure to risk factors for cancer,
such as smoking, varies according to gender and has to
be accounted for in explanations of gender diﬀerences.
In addition, women tend to seek health care more fre-
quently than men do and this might have aﬀected the
risk of cancer.30
Risk for cancer in persons with AIDS increases dra-
matically as they age, with a similar pattern seen in the
general population. Because PLWHA are living longer
and reaching older ages due to advances in disease
treatment, cancer in this population will remain an
important issue to be addressed. Strategies to promote
lifestyle changes to reduce or eliminate modiﬁable risk
factors such as tobacco smoking, as well as screening
and early cancer detection are key points for the man-
agement of cancer in PLWHA.
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Risk for cancer among people living with AIDS, 1997–2012:
the São Paulo AIDS–cancer linkage study
Luana F. Tanakaa,d,e, Maria R.D.O. Latorred,e, Eliana B. Gutierrezf,
Maria P. Curadog,h, Guenter Froeschla,b, Christian Heumannc and
Karl-Heinz Herbingerb
Previous studies have reported an increased risk for certain
types of cancer in the HIV-infected population. The aim of
this study was to assess the risk for cancer in people with
AIDS (PWA) in comparison with the general population in
São Paulo (Brazil), between 1997 and 2012. A population-
based registry linkage study was carried out to assess the
risk for cancer, using a standardized incidence ratio (SIR)
approach. A total of 480 102 person-years, of which 337 941
(70.4%) person-years were men, were included in the
analysis. Around 2074 cancer cases were diagnosed among
PWA, of which 51.0% were non-AIDS-defining cancers
(NADC). The risk for AIDS-defining cancers and NADC in the
male population with AIDS was significantly higher than
that in the general population (SIR= 27.74 and 1.87,
respectively), as it was in the female population with AIDS
compared with the general population (SIR= 8.71 and 1.44,
respectively). Most virus-related NADC occurred at elevated
rates among PWA: anal cancer (SIR= 33.02 in men and
11.21 in women), liver (SIR= 4.35 in men and 4.84 in
women), vulva and vagina (SIR= 6.78 in women) and
Hodgkin lymphoma (SIR= 5.84 in men and 2.71 in women).
Lung (SIR= 2.24 in men and 2.60 in women) and central
nervous system (SIR= 1.92 in men and 3.48 in women)
cancers also occurred at increased rates. Cancer burden
among PWA in São Paulo was similar to that described in
high-income countries such as the USA and Italy following
the introduction of the highly active antiretroviral therapy. As
coinfection with oncogenic viruses disproportionally affects
this population, virus-related cancers accounted for a great
share of excessive cases. European Journal of Cancer
Prevention 00:000–000 Copyright © 2017 Wolters Kluwer
Health, Inc. All rights reserved.
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Introduction
Since the beginning of the global AIDS epidemic, cancer
and AIDS have been closely linked. Kaposi sarcoma (KS)
and certain types of non-Hodgkin lymphoma were
among the first illnesses to be recognized as AIDS-
defining cancers (ADC) (CDC – Centers for Disease
Control and Prevention, 1982). Later in 1993, cervical
cancer (CC) was also classified as ADC (CDC – Centers
for Disease Control and Prevention, 1992).
The advent of the highly active antiretroviral therapy
(HAART) in 1996 has changed the course of the epi-
demic, by improving immune function and reducing
morbidity and mortality among HIV-infected people.
The incidence of ADC has decreased, and conversely the
proportion of non-AIDS-defining cancers (NADC)
among HIV-infected people has increased, surpassing
ADC (Engels et al., 2006; Dal Maso et al., 2009).
Previous studies conducted mainly in high-income
countries have shown that the increased risk for NADC
is largely due to virus-related cancers (Calabresi et al.,
2013; de Martel et al., 2015). According to the
International Agency for Research on Cancer, HIV
infection causes cancer indirectly by promoting immu-
nosuppression and enhancing the effects of oncogenic
infections (IARC – International Agency for Research on
Cancer, 2012).
In an effort to provide information on cancer risk among
people with AIDS (PWA) in a middle-income country,
the project entitled ‘São Paulo AIDS–Cancer Linkage
Study’ was conceived. This is the first population-based
study in Brazil describing cancer spectrum in PWA. The
aim of the present study was to compare the risk for
cancer among PWA with that in the general population
living in São Paulo.
Methods
In Brazil, notification of AIDS cases is compulsory since
1986, and cases diagnosed before then were retro-
spectively registered to the SINAN database (Sistema de
Research paper 1
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Informações de Agravos de Notificação/Information
System on Disease Notification).
The ‘Population-based Cancer Registry of São Paulo’
(PBCR-SP) covers 11 million inhabitants, residents in the
city of São Paulo according to the 2010 census (IBGE –
Instituto Brasileiro de Geografia e Estatística, 2016). This
registry collects, both actively and passively from all data
sources, cancer incidence among São Paulo inhabitants
since 1997.
In order to identify PWA who developed cancer, a
probabilistic record linkage was performed between the
SINAN and the PBCR-SP databases. Both databases
used in this study capture the same geographical area
(the city of São Paulo) and have high coverage (>90%)
(Latorre et al., 2015; SES-SP – Secretaria de Estado da
Saúde de São Paulo, 2015).
The study used a multistep strategy using the open
source software OpenReclink (version 2.9, Rio de
Janeiro, Brazil). Phonetic codes (soundex) of first and last
names and date of birth, as well as mother’s name and
address, when available were used in the process. A
clerical review was conducted at each step. Once true
matches were identified, registries were anonymized to
ensure data privacy.
To be included in the analysis the cases had to be
diagnosed with AIDS between 1980 and 2013, be at least
13 years of age at AIDS diagnosis and be a resident of the
city of São Paulo. Cancer cases that occurred 5 years or
earlier before AIDS diagnosis were excluded from the
analysis (n= 86), in addition to cases of basal cell skin
cancer (n= 173) and in-situ lesions (n= 238).
Cancer cases were classified and coded according to the
International Classification of Diseases for Oncology,
third edition (Fritz et al., 2000), and grouped into two
major groups – namely, ADC (KS, NHL and CC) and
NADC (all other cancers). Cancers were also grouped
according to their possible association with viruses
(Calabresi et al., 2013; de Martel et al., 2015).
Statistical methods
Crude incidence rates were calculated by dividing the
number of cases by the respective population at risk. To
compare the risk for cancer in the AIDS population
versus the general population, the standardized incidence
ratios (SIR), defined as SIR ¼number of observed casesnumber of expected cases and their
corresponding exact 95% confidence intervals were cal-
culated according to sex and site/type of cancer. To
obtain the expected number of cases in the AIDS
population during the 1997–2012 period, age-specific
incidence rates in the general population were provided
by the PBCR-SP for the same period. All statistical ana-
lyses were conducted using R (version 3.2.3).
Ethical clearance was obtained from the Ethics Review
Board at School Public Health, University of São Paulo
(686.849), the Municipal Health Secretariat of São Paulo
(703.467) and the University of Munich (233-15) before
study initiation.
Results
From 1980 through 2013, 87 109 cases of AIDS in indi-
viduals aged 13 years and older have been recorded in
the city of São Paulo (DATASUS – Departamento de
Informática do SUS, 2016). From 1997 to 2012, 496 276
invasive cancers (excluding basal cell skin cancer and
in situ) were registered in the city by the PBCR-SP.
The AIDS population at risk comprised a total of 480 102
person-years (PY), which consisted of mostly men
[337 941 (70.4%) PY] and patients aged 30–49 years
[285 006 (59.4%) PY]. Between 1997 and 2012, there
have been 2074 incident cancers cases in 2000 PWA.
Seventy-four patients had two primary site tumors
(3.7%). Overall, about half of the cancers [1057 (51.0%)]
were NADC.
The main characteristics of the 2000 people with AIDS
and cancer are shown in Table 1. Most patients were
male [1461 (73.0%)] and had acquired HIV through
sexual contact [1300 (65.0%)]. Patients who developed
ADC were significantly younger than those with NADC
(37.5 vs. 45.9 years, respectively; P< 0.001). The most
frequent cancer in men was KS, accounting for 31.1%
(n= 469) of all cases, and in women it was CC [114
(20.2%)], as seen in Tables 2 and 3.
In men with AIDS, the risk for ADC overall (SIR=27.74),
KS (SIR=86.95) and NHL (SIR=13.53) in particular was
significantly increased. NADC overall was also more frequent
Table 1 Characteristics of 2000 people living with AIDS and cancer.
São Paulo, 1997–2012
Characteristics Total Male Female
N 2000 1461 539
Age at AIDS-defining cancer onset
(median in years)
37.5 37.9 36.6
Age at non-AIDS-defining cancer
onset (median in years)
45.9 46.7 44.6
Race/ethnicity [n (%)]
White 1111 (55.6) 860 (58.9) 251 (46.6)
Nonwhite 412 (20.6) 253 (17.3) 159 (29.5)
Unknown 477 (23.9) 348 (23.8) 129 (23.9)
Exposure to HIV [n (%)]
Homosexual or bisexual contacta 626 (31.3) 626 (42.8) NA
Heterosexual contact 674 (33.7) 313 (21.4) 361 (67.0)
Intravenous drug use 145 (7.3) 105 (7.2) 40 (7.4)
Other 10 (0.5) 4 (0.3) 6 (1.1)
Unknown 545 (27.3) 413 (28.3) 132 (24.5)
Period at cancer diagnosis [n (%)]
1997–2001 697 (34.9) 542 (37.1) 155 (28.8)
2002–2006 647 (32.4) 430 (29.4) 217 (40.3)
2007–2012 656 (32.8) 489 (33.5) 167 (31.0)
NA, not applicable.
aThis category applies to men only.
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in PWA when compared with the general population
(SIR=1.87). The incidence of virus-related cancers was sig-
nificantly elevated in men with AIDS, with the highest risk
seen for anal cancer (SIR=33.02), followed by Hodgkin
lymphoma (SIR=5.84). The risk for cancer in women with
AIDS showed a similar pattern to that seen in men; there was
a significant increase in ADC overall (SIR=8.71), KS
(SIR=156.69), NHL (SIR=14.06) and CC (SIR=5.44) in
particular. NADC also occurred at higher rates in female
patients with AIDS (SIR=1.44), most notably for anal cancer
(SIR=11.21), tonsil and oropharynx (SIR=7.51), vulva and
vagina (SIR=6.78), nasopharynx (SIR=5.65) and liver
(SIR=4.84) (Table 3 and Figs 1 and 2).
Discussion
The present study identified an increased risk for cancer
among PWA in the city of São Paulo. All ADC and most
virus-related NADC occurred at higher rates in this
population. The manifestation of ADC occurred on
average 8 years earlier than that of NADC.
As expected, KS had the highest risk and was the most fre-
quent cancer overall in PWA in São Paulo. In the pre-
HAART era, when the incidence of KS peaked, SIR levels
greatly surpassed 1000 (Dal Maso et al., 2001). With the
introduction of HAART, the incidence of KS among HIV-
infected people dramatically decreased, but the risk remains
substantially higher when compared with the general popu-
lation (Engels et al., 2006). In São Paulo, the risk for KS was
about 100-fold, not as low as has been reported in Uganda
(Mbulaiteye et al., 2006), but not as high as in some European
countries (Galceran et al., 2007; Polesel et al., 2010).
Table 2 Number of expected and observed cases, standardized
incidence ratio and 95% confidence interval of cancers among men
with AIDS, according to cancer type/site. São Paulo, 1997–2012
Cancer types/sites (ICD-10
code) Observed Expecteda SIR 95% CI
All AIDS-defining cancers 773 27.86 27.74 25.85–29.77
Kaposi sarcoma (C46) 469 5.39 86.95 79.42–95.18
Non-Hodgkin lymphoma
(C82–C85; C96)
304 22.47 13.53 12.09–15.14
All non-AIDS-defining cancersb 737 394.79 1.87 1.74–2.01
Lip, mouth and pharynx
(C00–C14)
68 35.87 1.90 1.49–2.40
Tongue (C01–C02) 14 9.13 1.53 0.91–2.59
Tonsil and oropharynx
(C09–C10)
14 4.73 2.96 1.75–4.99
Nasopharynx (C11) 6 1.79 3.34 1.50–7.44
Esophagus (C15) 13 13.94 0.93 0.54–1.61
Stomach (C16) 37 25.81 1.43 1.04–1.98
Small intestine (C17) 6 1.85 3.24 1.45–7.20
Colon-rectum (C18–C20) 59 36.93 1.60 1.24–2.06
Anus and anal canal (C21) 63 1.91 33.02 25.80–42.27
Liver (C22) 18 4.14 4.35 2.74–6.91
Gall bladder and biliary tract
(C23–C24)
4 1.97 2.03 0.76–5.42
Pancreas (C25) 12 6.07 1.98 1.12–3.48
Nasal cavity (C30–C31) 2 1.39 1.44 0.36–5.75
Larynx (C32) 22 12.96 1.70 1.12–2.58
Lung (C33–C34) 54 24.15 2.24 1.71–2.92
Mediastinum (C37–C38) 3 1.02 2.93 0.95–9.09
Bone (C40–C41) 2 4.40 0.46 0.11–1.82
Melanoma (C43) 6 10.42 0.58 0.26–1.28
Skin nonmelanoma (C44)c 49 17.80 2.75 2.08–3.64
Connective tissue (C49) 11 6.38 1.72 0.95–3.11
Breast (C50) 3 2.30 1.30 0.42–4.04
Penis (C60) 6 3.39 1.77 0.80–3.94
Prostate (C61) 49 48.88 1.00 0.76–1.33
Testis (C62) 17 15.59 1.09 0.68–1.75
Kidney (C64–C66; C68) 15 11.19 1.34 0.81–2.22
Bladder (C67) 9 12.14 0.74 0.39–1.42
Eye (C69) 9 1.70 5.28 2.75–10.15
Central nervous system
(C70–C72)
27 14.04 1.92 1.32–2.80
Thyroid (C73) 10 20.17 0.50 0.27–0.92
Hodgkin lymphoma (C81) 49 8.39 5.84 4.42–7.73
Multiple myeloma (C90) 8 4.51 1.77 0.89–3.55
Leukemia (C91–C95) 21 13.34 1.57 1.03–2.41
Statistically significant results are presented in italics.
aNumber of expected cases rounded to nearest hundredth.
bIncluding 85 cases of ill-defined primary site.
cExcluding basal cell carcinoma.
Table 3 Number of expected and observed cases, standardized
incidence ratio and 95% confidence interval of cancers among
women with AIDS, according to cancer type/site. São Paulo,
1997–2012
Cancer type/site (ICD-10
code) Observed Expecteda SIR 95% CI
All AIDS-defining cancers 244 28.02 8.71 7.68–9.87
Kaposi sarcoma (C46) 34 0.22 156.69 111.96–219.29
Cervix (C53) 114 20.97 5.44 4.52–6.53
Non-Hodgkin lymphoma
(C82–C85; C96)
96 6.83 14.06 11.51–17.18
All non-AIDS-defining
cancersb
320 222.16 1.44 1.29–1.61
Lip, mouth and pharynx
(C00–C14)
13 5.06 2.57 1.49–4.42
Tongue (C01–C02) 1 1.01 0.99 0.14–7.04
Tonsil and oropharynx
(C09–C10)
5 0.67 7.51 3.13–18.04
Nasopharynx (C11) 2 0.35 5.65 1.41–22.60
Esophagus (C15) 2 1.18 1.69 0.42–6.76
Stomach (C16) 15 6.81 2.20 1.33–3.66
Colon-rectum (C18–C20) 19 15.51 1.23 0.78–1.92
Anus and anal canal (C21) 10 0.89 11.21 6.03–20.83
Liver (C22) 4 0.83 4.84 1.82–12.90
Gall bladder and biliary
tract (C23–C24)
4 1.21 3.32 1.24–8.84
Pancreas (C25) 2 2.11 0.95 0.24–3.78
Larynx (C32) 3 1.06 2.82 0.91–8.76
Lung (C33–C34) 17 6.54 2.60 1.62–4.18
Bone (C40–C41) 3 1.43 2.10 0.68–6.52
Melanoma (C43) 2 4.60 0.43 0.11–1.74
Skin nonmelanoma (C44)c 17 5.53 3.08 1.91–4.95
Connective tissue (C49) 2 2.59 0.77 0.19–3.09
Breast (C50) 72 76.20 0.94 0.75–1.19
Vulva and vagina
(C51–C52)
14 2.06 6.78 4.02–11.45
Uterus (C54–C55) 13 6.63 1.96 1.14–3.38
Ovary (C56) 16 8.42 1.90 1.16–3.10
Kidney (C64–C66; C68) 3 2.55 1.18 0.38–3.65
Bladder (C67) 5 2.26 2.22 0.92–5.32
Eye (C69) 2 0.66 3.04 0.76–12.15
Central nervous system
(C70–C72)
16 4.60 3.48 2.13–5.68
Thyroid (C73) 18 37.50 0.48 0.30–0.76
Adrenal and other
endocrine glands
(C74–C75)
2 0.58 3.45 0.86–13.78
Hodgkin lymphoma (C81) 9 3.32 2.71 1.41–5.21
Multiple myeloma (C90) 3 1.62 1.85 0.60–5.74
Leukemia (C91–C95) 5 4.40 1.14 0.47–2.73
Statistically significant results are presented in italics.
aNumber of expected cases rounded to nearest hundredth.
bIncluding 29 cases of ill-defined primary site.
cExcluding basal cell carcinoma.
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Epstein–Barr virus is significantly more frequently
involved in the oncogenesis of NHL, Hodgkin lymphoma
and nasopharyngeal carcinoma. In the present study, all
these cancers were found to affect PWA, as seen in
previous studies (Shiels et al., 2009). Rates of NHL among
PWA in São Paulo were ∼ 13-fold that in the general
population, considerably lower than that reported in the
USA and Europe (Galceran et al., 2007; Polesel et al., 2010).
Fig. 1
Standardized incidence ratio of AIDS-defining cancers, according to possible oncogenic virus. São Paulo, 1997–2012. Standardized incidence ratio
and respective confidence intervals are displayed on a log scale. EBV, Epstein–Barr virus; HPV, human papilloma virus; KSHV, Kaposi’s sarcoma-
associated herpesvirus.
Fig. 2
Standardized incidence ratio of virus-related non-AIDS-defining cancers, according to possible oncogenic virus. São Paulo, 1997–2012.
Standardized incidence ratio and respective confidence intervals are displayed on a log scale. EBV, Epstein–Barr virus; HBV, hepatitis B virus; HCV,
hepatitis C virus; HPV, human papilloma virus.
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Currently, there are consistent data attributing excess
cancer cases among HIV-infected people to oncogenic
viruses such as human papilloma virus (HPV),
Epstein–Barr virus, hepatitis B virus (HBV) and hepatitis
C virus (HCV) (Calabresi et al., 2013; de Martel et al.,
2015).
The infection with oncogenic HPV strains is associated
with the development of cancers of the cervix, anus,
vulva, vagina, penis, tongue, tonsil and oropharynx.
Association with tobacco smoking, in many cases, further
increases the risk for cancer (Cogliano et al., 2005). With
the exception of cancers of the tongue and penis, all
cancer sites associated with HPV infection occurred at
increased rates among PWA.
In the present study, anal cancer presented the highest
risk among NADCs in both sexes. Apart from a study
conducted in Uganda, which did not find an increased
risk for anal cancer among PWA, studies have found SIRs
ranging from 18 to 75 (Shiels et al., 2009). It is estimated
that HPV-infection accounts for as many as 93% of all
anal squamous cell cancers (Gillison et al., 2008). In
Brazil, among men who have sex with men with HIV/
AIDS, the prevalence of coinfection was found to be
40.7% (Guimaraes et al., 2011). In the present study, most
but not all men with AIDS who had this malignancy
reported being men who have sex with men. Women
with AIDS are also more likely to be affected by high-risk
HPV anal infection compared with HIV-uninfected
women. In a cohort of 863 HIV-infected women in Rio
de Janeiro, 51% had anal infection with high-risk carci-
nogenic HPV and 31% had abnormal anal cytology
(Cambou et al., 2015).
Cervical cancer and cancers of the vulva, vagina and
uterus were more frequent among women with AIDS.
Although uterus presented a higher risk in women with
AIDS, it is possible that a part of these cases could have
been misclassified and were actually CC, especially cases
of advanced disease (Loos et al., 2004). CC, vulvar and
vaginal cancers are all HPV-associated and high-risk HPV
types are frequently found in the anogenital area of HIV-
infected women (Castilho et al., 2015). São Paulo has a
CC screening program based on Pap smear for women
aged 25–64 years, whose coverage surpasses 90%
(CEInfo – Coordenação de Epidemiologia e Informação,
2010). Among HIV-infected women, current national
guidelines recommend annual Pap smear screening,
regardless of age. Although there is no information on
screening uptake in this population, in the present study,
about 40% of women were diagnosed with CC 1 year or
later after AIDS diagnosis, suggesting that adjustments to
current practice may be needed (Franceschi and Jaffe,
2007).
Among PWA, the overall risk for head and neck malig-
nancies was elevated, particularly for tonsillar and oro-
pharyngeal cancers, two HPV-related cancer sites. Oral
infection with HPV, although not as frequent as in the
anogenital area, seems to be higher among HIV-infected
people than in uninfected individuals (Matos et al., 2015).
The recent introduction of the HPV vaccine for young
girls and boys (9–13 years) and for HIV-infected patients
(9–26 years) will likely contribute to a future reduction in
the burden of HPV-related cancers in these cohorts, but
not in older patients.
The incidence of liver cancer among PWA was approxi-
mately four-fold higher than that in the general popula-
tion, in accordance with previous research (Shiels et al.,
2009). In São Paulo, viral hepatitis accounted for ∼ 6% of
all deaths among PWA (Domingues and Waldman, 2014).
Since 1998 the city offers HBV vaccination free of charge;
nevertheless, its coverage in adults (15–64 years-old) was
only 15.3% in 2014 (SMS-SP – Secretaria Municipal de
Saúde de São Paulo, 2014). In 2015, daclatasvir, sofos-
buvir and simeprevir were added as options to treat HCV
and could raise rates of cure to over 90% (MS – Ministério
da Saúde. Secretaria de Vigilância em Saúde, 2015). The
vaccination against HBV and the treatment for HCV will
likely contribute to a future reduction in the incidence of
hepatitis-associated liver cancer in this population.
Concerning gastric cancer, existing data are conflicting
(Shiels et al., 2009). In São Paulo, an excess of cases was
found among PWA. Infection with Helicobacter pylori is a
known risk factor for noncardia gastric cancer
(EUROGAST Study Group, 1993), but coinfection
among HIV-infected people seems to be low (Fialho
et al., 2011). Therefore, other exposures such as smoking
and alcohol consumption could have contributed to this
risk pattern.
Several studies have already described increased rates of
lung cancer among HIV-infected people, as seen in this
study. Some pieces of evidence indicate that the excess
risk for lung cancer in this population is mainly due to
increased smoking, rather than HIV-associated immu-
nosuppression or pulmonary disease (Clifford et al., 2012).
In line with the results from a study conducted in Uganda
(Mbulaiteye et al., 2006), the risk for eye cancer was
increased in men with AIDS. Exposure to sunlight is a
known risk factor for this malignancy. In São Paulo, the
ultraviolet irradiation is frequently high even during
winter and can reach extreme levels in the summer (de
Paula Correa and Ceballos, 2010). In addition to sunlight,
there is growing evidence that HPV is also involved in
the oncogenesis of eye cancer (Carreira et al., 2013).
Moreover, in accordance with previous studies, PWA
developed nonmelanoma skin cancer at higher rates
(Shiels et al., 2009). Exposure to sunlight and skin pho-
totype are known risk factors for these malignancies.
Among HIV-infected people, immune suppression
seems to be associated with the occurrence of squamous
cell carcinoma, and recent research suggests that HPV
Cancer in people with AIDS in São Paulo Tanaka et al. 5
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might also contribute to its oncogenesis (Silverberg et al.,
2013).
Although elevated rates of brain tumors have been
identified in both sexes, results should be interpreted
with caution, because only 23.3% of cases were micro-
scopically confirmed. Cases of primary central nervous
system lymphomas or other HIV-related malignancies
could have been misclassified as brain tumors, resulting
in inflated SIRs.
A causal hypothesis could not be developed for the
increased rates of certain cancers, such as small intestine,
colon-rectum and gall bladder among PWA. These sig-
nificant findings were restricted to sex and were not
consistent with previous studies (Shiels et al., 2009).
These correlations have to be reconfirmed through future
studies, and potentially explanatory models need to be
investigated.
The estimated SIR of several cancer sites, such as breast,
prostate, bladder and esophagus did not differ from 1 : 1,
in agreement with other investigations (Shiels et al.,
2009).
This study has limitations inherent to its design. As an
ecological study, this study has low analytical capacity,
being essentially descriptive. The record linkage itself
could be a source of error if it fails in identifying some
patients with both AIDS and cancer, resulting in under-
estimation of SIR. To keep this error minimal, a multi-
step process and clerical review were used in each step.
These strategies have already been proven effective
when linking the PBCR-SP and the mortality system to
complete patients’ follow-up, as a part of the registry’s
routine (Peres et al., 2014). As the AIDS database was
conceived primarily for administrative purposes, detailed
information on patients’ clinical conditions were not
available. The analyses were restricted to PWA and did
not include HIV-only patients.
This study also has strengths. It is one of the first
population-based studies in South America assessing the
risk of cancer among PWA. As the largest city in Brazil,
São Paulo accounts for more cases of AIDS compared
with any other city (12.6% of all cases) in the country.
Almost 500 000 PY were included in the analysis, and the
number of cancer cases allowed for stratification by sex.
Although the catchment area of this study has been
restricted to São Paulo, it is possible that similar patterns
could be identified in other capitals or large cities in
Brazil with comparable population profiles. These results
provide useful information to local health authorities that
can be used to plan and adapt current health policies,
such as early detection and routine vaccination aimed at
HIV-infected people.
The present study revealed a similar pattern for the risk
for cancer among PWA as has been described in other
countries (Shiels et al., 2009). As coinfection with
oncogenic viruses disproportionally affects these indivi-
duals, virus-related NADC accounted for an important
share of excessive cases. Modifiable risk factors, such as
tobacco smoking and alcohol consumption, might have
also contributed to this scenario. A fraction of these cases
could have been prevented if exposure to these risk
factors were reduced.
Since 2013, the Brazilian Ministry of Health recommends
the initiation of HAART immediately after diagnosis,
regardless of CD4 count (MS – Ministério da Saúde.
Secretaria de Vigilância em Saúde, 2013). Early initiation
of HAART could also contribute to reduce cancer risk
among HIV-infected people, in particular those asso-
ciated with known viruses. However, the success of this
strategy depends on the ability of the health system to
diagnose HIV-infected patients in time.
Primary prevention, including strategies to encourage
smoking cessation and reduce alcohol consumption,
vaccination against potentially oncogenic viruses such as
HPV and HBV, and effective treatment of chronic
infections including HAART, are important tools in the
management of cancer among HIV-infected people.
Early cancer detection through screening and timely
treatment could further contribute to reduced morbidity
and mortality in this population. Although the current
Brazilian guidelines for the management of HIV address
some of these issues, cancer will remain a major concern
with the growth and ageing of the HIV-infected
population.
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8. Conclusion
In this session, the main conclusions of the study are presented according to the objectives stated 
in Session 2 (Rationale and Objectives). 
8.1. There was a significant declining trend in the incidence of AIDS-defining cancers in men and 
women. However, an upward trend in non-AIDS-defining cancers starting in the mid 2000´s has been 
identified in men with AIDS, driven by lung and anal cancers. 
8.2. The overall risk of cancer was significantly higher in people with AIDS when compared to the 
general population. Most virus-related cancers occurred at significantly higher rates in this population. 
8.3. The five-year overall survival after cancer diagnosis was significantly lower in people with AIDS 
than that of matched controls from the general population.  
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Cancer survival in people with AIDS: A population-based study
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Cancer survival among people with AIDS (PWA) has been described in developed countries, but there is lack of data from
developing countries. The aim of this study was to evaluate survival after cancer diagnosis in PWA and compare it with people
without AIDS (non-PWA) in S~ao Paulo, Brazil. A probabilistic record linkage was carried out between the databases of the Pop-
ulation-based Cancer Registry of S~ao Paulo (PBCR-SP) and the AIDS registry of SP (SINAN) to identify PWA who developed can-
cer. For comparison, non-PWA were frequency matched from the PBCR-SP by cancer site/type, sex, age, and period. Hazard
ratio (HR) stratified by matching variables was estimated using a Cox proportional hazards model. A total of 1,294 PWA (20
patients with two primary site tumors) were included in the site/type-specific analyses. AIDS-defining cancers (ADC) comprised
51.9% of cases assessed. The all-cancer 5-year overall survival in PWA was 49.4% versus 72.7% in non-PWA (HR52.64;
95%CI52.39–2.91). Survival was impaired in PWA for both ADC (HR52.93; 95%CI52.49–3.45) and non-ADC (HR52.51;
95%CI52.21–2.84), including bladder (HR58.11; 95% CI52.09–31.52), lung (HR52.93; 95%CI51.97–4.36) and anal can-
cer (HR52.53; 95%CI51.63–3.94). These disparities were seen mainly in the first year after cancer diagnosis. The overall
survival was significantly lower in PWA in comparison with non-PWA in S~ao Paulo, as seen in high-income countries. Efforts to
enhance early diagnosis and ensure proper cancer treatment in PWA should be emphasized.
Introduction
The introduction of the highly active antiretroviral therapy
(HAART) has greatly improved life expectancy among HIV-
infected individuals, turning the infection into a chronic condi-
tion and consequently enlarging the HIV-infected population.1,2
People with AIDS (PWA) are at increased risk for several
types of cancers, both AIDS-deﬁning (ADC), such as Kaposi
sarcoma (KS), non-Hodgkin lymphoma (NHL) and cervical
cancer (CC) and non-AIDS-deﬁning (NADC) such as lung,
anal and Hodgkin lymphoma (HL).3–6 Impaired immune
response, co-infections with potentially oncogenic viruses,
such as the human papilloma virus, hepatitis B and C viruses
and higher frequency of exposure to tobacco smoking are
some of the known factors associated with an increased risk
for cancer.5
Increasing trends in cancer-related mortality in PWA have
been reported in Brazil7 and other countries.8 In the city of
S~ao Paulo (Brazil), the proportion of cancer-related deaths in
PWA has increased from 6.2% in the pre-HAART era (1991–
1996) to 10.1% in the late post-HAART era (2000–2006) and
is likely to reach even higher proportions as this population
is living longer and reaching older ages.8,9 Nevertheless, sur-
vival after cancer diagnosis at a population level has been less
explored, especially in low- and middle-income countries.10,11
S~ao Paulo is the largest city in South America and one of the
largest worldwide, home to over 12 million inhabitants.12
Brazil was the ﬁrst developing country to provide universal
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treatment when HAART became available in 1996 and has
developed over the years an internationally recognized AIDS
program.13 In 2013, the country expanded HAART to all
HIV-infected people regardless of CD4 count. These unique
features make S~ao Paulo a place of interest to study AIDS-
related malignancies in this particular population.14
The existence of a population-based cancer registry in S~ao
Paulo and the mandatory notiﬁcation of AIDS since the ﬁrst
years of the epidemic enable the conduction of a population-
based study. Its objective was to describe the 5-year overall
survival after cancer diagnosis in PWA and compared this to
that of selected controls from the general population in S~ao
Paulo.
Methods
A probabilistic record linkage was conducted to identify
patients with AIDS who were diagnosed with cancer. To
summarize brieﬂy this procedure, the database of the
“Population-based Cancer Registry of S~ao Paulo” (PBCR-
SP) which contains 628,161 cancer cases diagnosed from
1997 to 2012 was linked to the Sistema de Informac¸~ao de
Agravos de Notiﬁcac¸~ao/Information System on Disease Noti-
ﬁcation database (SINAN) which comprises 87,109 records
of people diagnosed with AIDS from 1980 through 2013.
Both databases have high coverage and comprehend the
same geographical area, namely the city of S~ao Paulo.15,16
Therefore, our study is restricted to S~ao Paulo residents
only.
In the linkage process, the records were compared based
on patient’s full name and date of birth using the open
source software OpenRecLink (version 2.9). A multi-step pro-
cedure was employed and clerical review of matches, based
on mother’s name and address, was carried out to improve
both sensitivity and speciﬁcity. After true matches had been
identiﬁed all personal identiﬁers were removed from the
database to ensure data privacy.
Exclusion criteria were the following: in situ cancers,
cancers reported by death certiﬁcate only (DCO), cancers
diagnosed before AIDS and cancers diagnosed from 2010
onwards leading to incomplete follow up (considering 31st
December, 2014 as the end of the observation period),
patients aged 75 years and older and patients with two pri-
mary non-melanoma skin cancers (NMSC), in that case only
the earliest tumor was considered.
Selection of subjects
The record linkage procedure identiﬁed 2,571 cancers in
PWA. However, 1,257 cases were excluded from the survival
analyses as follows: 238 in situ cancers; 281 cancers reported
by DCO, 394 cancers diagnosed before AIDS; 323 cancers
diagnosed from 2010 onwards; 15 patients aged 75 years and
older and six patients with two primary NMSC.
To compare survival probabilities between PWA and peo-
ple from the general population without AIDS (non-PWA), a
control group has been randomly selected following the
approach described in a previous study.11 Our study consid-
ered as non-PWA all subjects who could not be matched dur-
ing the record linkage procedure. A random matching in a
4:1 (non-PWA:PWA) ratio was conducted for all cancer
types/sites, with the exception of non-Hodgkin lymphoma
(2:1), due to the insufﬁcient cases in the general population.
Matching by cancer site, histology (third revision of the Inter-
national Classiﬁcation of Diseases for Oncology, ICD-O-3),
age Group (10-year age bands), sex and period at cancer diag-
nosis (1997–2000, 2001–2004 and 2005–2009) was prioritized,
and when not possible fewer matching variables were used
until the matching procedure was possible. In the case of KS,
all matching attempts had failed because KS in non-PWA is a
rare condition in S~ao Paulo; hence, a 1:1 ratio for controls
was used, respecting the same age range (15–74 years).
Patients with two primary tumors were included only
once in the combined analyses (all-cancer, all-ADC and all-
NADC). In this case, the ﬁrst tumor or the one with the
poorest prognosis was considered.
Statistical methods
The PBCR-SP conducts routine record linkage with the ofﬁ-
cial mortality database of S~ao Paulo, ensuring updated vital
status of cancer patients. For PWA, information on death
was also available in the AIDS data set.
Patients included in the analyses were followed up for 5
years, until the outcome of interest (death from any cause) was
observed or the end of the observation period was reached (31st
December, 2014), whichever occurred earlier. For those patients
who survived beyond this threshold, time was right-censored.
Kaplan–Meier survival curves were estimated. To compare
the risk for death according to AIDS status (PWA vs. non-
PWA), the estimated hazard ratios (HR) and the respective
95% conﬁdence intervals (95%CI) were calculated by means
of the Cox proportional hazards model, stratiﬁed by
What’s new?
While increasing trends in cancer-related mortality in people with AIDS have been widely reported, survival after cancer diag-
nosis remains less explored. This is the first population-based study in Brazil and one of the few conducted in developing
countries assessing cancer survival in people with AIDS. The large sample size allowed stratification by cancer type/site and
analysis of 22 non-AIDS-defining cancers. The results revealed an impaired 5-year overall survival after cancer diagnosis in
people with AIDS in comparison to the general population, suggesting that national guidelines for the prevention, early diag-
nosis and management of cancer among HIV-infected people may be beneficial.
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matching variables and adjusted for age (in years). These esti-
mates were provided according to cancer type/site. Cancers
were also grouped into AIDS-deﬁning (KS, NHL and CC)
and non-AIDS-deﬁning (all other). To describe early and late
risk, as presented by other studies, the HRs for 1- and 5-year
survival (conditional on surviving the ﬁrst year) were
estimated.11,17 In addition, the survival analyses were also
stratiﬁed by sex and age group (<40 years vs. 40 years),
separately to allow for comparison to a previous study.11 The
proportional hazard assumption was graphically assessed
based on plots of the log(-log(survival probability)) vs. log
(time) and all models met this criterion. This graph shows
Table 1. Characteristics of people with AIDS and cancer and of controls from the general population. S~ao Paulo, 1997–2009
People with AIDS
Total ADC NADC
People without
AIDS1
N % N % N % N %
Sex
Male 951 73.5 517 77.0 434 69.7 1,988 61.3
Female 343 26.5 154 23.0 189 30.3 1,252 34.2
Age at cancer diagnosis (years)
15–19 4 0.3 3 0.5 1 0.2 8 0.2
20–29 157 12.1 119 17.7 38 6.1 243 7.5
30–39 441 34.1 286 42.6 155 24.9 959 29.6
40–49 383 29.6 172 25.6 211 33.9 1,052 32.5
50–59 221 17.1 75 11.2 146 23.4 666 20.6
60–69 73 5.6 14 2.1 59 9.5 256 7.9
70–74 15 1.2 2 0.3 13 2.1 56 1.7
Age at AIDS diagnosis (years)
15–19 12 0.9 9 1.3 3 0.5 – –
20–29 239 18.5 157 23.4 82 13.2 – –
30–39 494 38.2 279 41.6 215 34.5 – –
40–49 335 25.9 152 22.7 183 29.4 – –
50–59 165 12.8 64 9.5 101 16.2 – –
60–69 46 3.6 9 1.3 37 5.9 – –
70–74 3 0.2 1 0.2 2 0.3 – –
Exposure to HIV
Homosexual men 306 23.7 198 29.5 108 17.3 – –
Bisexual men 140 10.8 74 11.0 66 10.6 – –
Heterosexual 432 33.4 198 29.5 234 37.6 – –
Intravenous drug use 113 8.7 43 6.4 70 11.2 – –
Other 5 0.4 4 0.6 1 0.2 – –
Unknown 298 23.0 154 23.0 144 23.1 – –
Year of cancer diagnosis
1997–2000 443 34.2 302 45.0 141 22.6 937 28.9
2001–2004 351 27.1 182 27.1 169 27.1 918 28.3
2005–2009 500 38.6 187 27.9 313 50.2 1,385 42.8
Period of AIDS diagnosis
Pre-HAART (before 1996) 217 16.8 92 13.7 125 20.1 – –
HAART (1996 onwards) 1,077 83.2 579 86.3 498 79.9 – –
Total 1,294 100 671 100 623 100 3,240 100
1Excluding cases of Kaposi sarcoma for which no matching strategy was employed.
Sources: Population-based Cancer Registry of S~ao Paulo and Sistema de Informac¸~ao de Agravos de Notificac¸~ao (SINAN).
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the hazards over time and when curves are parallel, the
assumption of proportionally is not violated.18
The statistical analyses were carried out in Stata (version
13) using anonymized records. This research is part of the
“S~ao Paulo AIDS-Cancer Linkage Study” and obtained ethical
clearance from all institutions concerned: the School of
Public Health (686.849), Municipal Health Secretariat of S~ao
Paulo (703.467) and the University of Munich (233–15).
Results
A total of 1,294 PWA were included in the cancer type/site-
speciﬁc survival analysis, of which 20 (1.5%) PWA had two
primary site tumors. These 20 PWA were considered only
once in the all-cancer and respective all-ADC and all-NADC
analyses.
The descriptive analysis was based on 1,294 patients
(Table 1). The majority of PWA were male (951; 73.5%) and
aged 30–49 years at cancer diagnosis (824; 63.7%). Sexual
contact was the main mode of exposure to HIV (878; 67.9%).
There was a slight predominance of ADC in relation to
NADC in the period as a whole, but the ADC:NADC ratio
shifted from 2.1:1 (1997–2000) to 0.6:1 (2005–2009),
highlighting that NADC are already more frequent than
ADC among PWA in S~ao Paulo. Over 40% of ADC were
Table 2. Hazard ratio of death and corresponding 95% confidence intervals at 5-years after cancer diagnosis by cancer type. S~ao Paulo,
1997–2009
People with AIDS People without AIDS
Cancer type/site Cases Deaths Survival (%) Cases Deaths Survival (%) HR (95% CI)1,2
All3 1,294 655 49.4 3,610 986 72.7 2.64 (2.39–2.91)
ADC3 671 333 50.4 1,118 257 77.0 2.93 (2.49–3.45)
KS 373 162 56.6 373 46 87.7 3.66 (2.59–5.19)
NHL 228 146 36.0 456 142 68.9 3.02 (2.43–3.76)
CC 73 28 61.6 292 70 76.0 2.02 (1.34–3.04)
NADC3 623 322 48.3 2,492 729 70.7 2.51 (2.21–2.84)
Head and neck 63 44 30.2 252 114 54.8 1.78 (1.28–2.48)
Esophagus 6 3 50.0 24 16 33.3 0.57 (0.11–2.89)
Stomach 26 19 26.9 104 52 50.0 1.90 (1.16–3.14)
Colon-rectum 32 22 31.3 128 44 65.6 3.46 (1.99–5.99)
Anus 43 23 46.5 172 48 72.1 2.53 (1.63–3.94)
Liver 9 8 11.1 36 22 38.9 3.43 (1.40–8.39)
Gallbladder 6 4 33.3 24 16 33.3 0.74 (0.28–1.93)
Lung 38 34 10.5 152 99 34.9 2.93 (1.97–4.36)
NMSC 126 37 70.6 504 33 93.5 5.39 (3.53–8.22)
Breast 40 15 62.5 160 31 80.6 2.72 (1.53–4.83)
Vulva and vagina 9 2 77.8 36 5 86.1 1.94 (0.50-7.51)
Ovary 6 2 66.7 24 6 75.0 1.23 (0.19–7.88)
Prostate 23 9 60.9 92 14 84.8 6.07 (2.39–15.45)
Testis 9 4 55.6 36 4 88.9 3.45 (0.96–12.32)
Kidney 9 6 33.3 36 12 66.7 5.14 (1.63–16.24)
Bladder 9 6 33.3 36 5 86.1 8.11 (2.09–31.52)
Eye 7 1 85.7 28 1 96.4 4.93 (0.49–49.64)
CNS 17 14 17.6 68 48 29.4 3.08 (1.64–5.80)
Thyroid 15 2 86.7 60 2 96.7 3.79 (0.60–24.01)
HL 36 17 52.8 144 30 79.2 2.75 (1.61–4.69)
Multiple myeloma 7 4 42.9 28 8 71.4 4.05 (1.27–12.89)
Leukemia 14 12 14.3 56 33 41.1 2.90 (1.52–5.54)
Other 90 41 54.4 360 99 72.5 1.77 (1.29–2.44)
1HR stratified by matching variables and adjusted for age (in years) at cancer diagnosis.
2Matched by cancer type (1:1 for KS, 1:2 for NHL, 1:4 for other cancers), sex, age and period of diagnosis.
3People with two primary site cancers were included only once in the analysis.
Sources: Population-based Cancer Registry of S~ao Paulo and Sistema de Informac¸~ao de Agravos de Notificac¸~ao (SINAN).
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diagnosed between 1997 and 2000, whereas, half of NADC in
the 2005–2009 period. Concerning the period of AIDS diag-
nosis, most patients (1,077; 83.2%) had been diagnosed in
the post-HAART period.
Among ADC cases, 373 were KS (28.4%). As for NADC,
the most frequent cancer was NMSC, including basal cell car-
cinoma (126; 9.6%), followed by head and neck (63; 4.8%).
All type/site-speciﬁc percentages were calculated based on
1,314 records.
The all-cancer 5-year overall survival among PWA was
49.4% (vs. 72.7% in matched non-PWA) and the death HR
(PWA vs. non-PWA) was 2.64 (95%CI5 2.39–2.91). The
death HRs were further 2.93 for ADC (95%CI5 2.49–3.45)
and 2.51 (95%CI5 2.21–2.84) for NADC. The type/site-spe-
ciﬁc analyses revealed that for the majority of malignancies
assessed, PWA died more frequently. The highest HRs were
found for cancers of the bladder (HR5 8.11; 95%CI5 2.09–
31.52), prostate (HR5 6.07; 95%CI5 2.39–15.45) and NMSC
(HR5 5.39; 95%CI5 3.53–8.22). Survival did not differ
according to AIDS status for cancers of the esophagus, ovary
and thyroid (Table 2).
In PWA, the poorest survival was observed for lung cancer
(10.5%), followed by liver cancer (11.1%) and leukemia (14.3%).
Conversely, the highest survival probabilities were seen for can-
cers of the thyroid (86.7%), eye (85.7%), vulva and vagina
(77.8%) and NMSC (70.6%). The survival curves for ADC and
selected NADC can be found in Figures 1 and 2, respectively.
The results of the 1- and 5-year survival (conditional on sur-
viving the ﬁrst year) analyses after cancer diagnosis are shown
in Table 3. For lung cancer (HR5 3.20; 95%CI5 2.10–4.89),
leukemia (HR5 4.00; 95%CI5 2.04–7.83) NHL (HR5 3.73;
95%CI5 2.90–4.80), among others, the survival gap was
restricted to the ﬁrst year after diagnosis. However, for anal,
breast and prostate cancers, risk differences emerged after the
ﬁrst year of diagnosis. For head and neck cancer, NMSC and
CC survival disparities could be observed throughout the entire
period.
In the stratiﬁed analyses by age group and sex no differences
were found when comparing groups. Although not statistically
signiﬁcant, the HRs for most cancers assessed tended to be
higher in younger (<40 years) than in older patients (40
years) (Table 4).
Figure 1. Five-year overall survival after diagnosis of AIDS-defining cancers by AIDS status. S~ao Paulo, 1997–2009.
Note: Matched by cancer type (1:1 for KS, 1:2 for NHL, 1:4 for cervical cancer), sex, age and period of diagnosis.
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Discussion
The aim of our study was to compare survival after cancer in
PWA and non-PWA. The results revealed that in S~ao Paulo
all-cancer 5-year overall survival was signiﬁcantly lower in
PWA than in non-PWA with the same cancer type/site, sex
and age (49.4% vs. 72.7%), as reported in previous studies
using population-based data.10,11
Despite ADC being somewhat more frequent in the period
as a whole, NADC had already become more incident in
2005–2009, reﬂecting the changing AIDS epidemic since the
advent of HAART, a well-documented phenomenon in high-
income countries.19 Studies which compared cancer survival
before and after HAART revealed that the gap between HIV-
infected and their uninfected counterparts narrowed, but still
Figure 2. Five-year overall survival after diagnosis of selected non-AIDS-defining cancers by AIDS status. S~ao Paulo, 1997–2009.
Note: Matched by cancer type (1:1 for KS, 1:2 for NHL, 1:4 for other cancers), sex, age and period of diagnosis.
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remained signiﬁcant for most cancers, as seen in S~ao
Paulo.10,11
In the type/site-speciﬁc analyses, the probability of survival
was impaired in PWA for all ADC and most NADC, in accor-
dance with previous ﬁndings using a similar approach.11 The
lowest survival probabilities were found for cancers of the lung,
liver and central nervous system (CNS), malignancies with
generally poor prognosis. Survival after lung cancer has been
described earlier.10,11,20–24 While some studies reported com-
parable survival rates between the two populations10,20,21 our
study identiﬁed poorer outcomes among PWA.11,22–24 These
discrepancies may arise from the diversity of strategies used for
the selection of controls and also the HR adjustments. Unlike
other studies,10,11,24 in S~ao Paulo, PWA had greater risk of
death of anal cancer (HR5 2.53), but this gap appeared only
after the ﬁrst year of diagnosis.
In contrast to non-PWA, survival for leukemia ranked
among the least favorable in PWA (14.3%). In a study con-
ducted in Italy, all six patients with leukemia had already
died by the end of the ﬁrst year of follow up, the poorest
Table 3. Hazard ratio of death and corresponding 95% confidence intervals at 1 and 5 years (conditional on surviving the first year) after can-
cer diagnosis by cancer type. S~ao Paulo, 1997–2009
1-Year survival
5-Year survival (conditional on
surviving the 1st year)
Cancer type/site Cases Deaths HR (95% CI)1 Cases Deaths HR (95% CI)1,2
All3 1,294 464 2.90 (2.58–3.26) 830 191 2.18 (1.82–2.60)
ADC3 671 261 3.77 (3.09–4.60) 410 72 1.66 (1.21–2.27)
KS 373 124 6.67 (3.88–11.47) 249 38 1.73 (1.02–2.96)
NHL 228 124 3.73 (2.90–4.80) 104 22 1.33 (0.83–2.13)
CC 73 16 1.92 (1.16–3.16) 57 12 2.24 (1.18–4.24)
NADC3 623 203 2.49 (2.14–2.90) 420 119 2.53 (2.05–3.13)
Head and neck 63 25 1.79 (1.20–2.67) 38 19 1.74 (1.04–2.92)
Esophagus 6 1 0.31 (0.02–3.80) 5 2 *
Stomach 26 16 1.99 (1.17–3.38) 10 3 1.61 (0.51–5.04)
Colon-rectum 32 16 4.62 (2.20–9.71) 16 6 2.01 (0.81–4.97)
Anus 43 7 1.43 (0.66–3.09) 36 16 4.04 (2.18–7.49)
Liver 9 6 3.89 (1.23–12.23) 3 2 3.46 (0.32–37.81)
Gallbladder 6 3 0.77 (0.25–2.35) 3 1 *
Lung 38 30 3.20 (2.10–4.89) 8 4 1.47 (0.51–4.22)
NMSC 126 14 11.57 (4.84–27.65) 112 23 4.18 (2.55–6.84)
Breast 40 4 2.73 (0.93–7.98) 36 11 2.87 (1.40–5.90)
Vulva and vagina 9 1 2.35 (0.25–22.03) 8 1 1.57 (0.31–8.08)
Ovary 6 2 3.05 (0.57–16.37) 4 – *
Prostate 23 3 5.32 (0.81–35.17) 20 6 6.39 (2.24–18.22)
Testis 9 3 3.66 (0.85–15.82) 6 1 2.42 (0.38–15.46)
Kidney 9 2 1.75 (0.31–9.83) 7 4 24.14 (2.48–234.61)
Bladder 9 4 15.18 (1.36–169.47) 5 2 4.21 (0.88–20.17)
Eye 7 1 4.93 (0.49–49.64) 6 – *
CNS 17 11 3.67 (1.84–7.29) 6 3 1.96 (0.64–5.98)
Thyroid 15 1 * 14 1 1.83 (0.15–23.12)
HL 36 12 3.00 (1.55–5.81) 24 5 2.40 (0.87–6.64)
Multiple myeloma 7 4 4.12 (1.26–13.46) 3 – *
Leukemia 14 11 4.00 (2.04–7.83) 3 1 0.63 (0.08–4.87)
Other 90 28 1.71 (1.16–2.51) 62 13 1.92 (1.06–3.48)
1HR stratified by matching variables and adjusted for age (in years) at cancer diagnosis.
2Matched by cancer type (1:1 for KS, 1:2 for NHL, 1:4 for other cancers), sex, age and period of diagnosis.
3People with two primary site cancers were included only once in the analysis.
*HR not available due to insufficient number of events among cases or controls.
Sources: Population-based Cancer Registry of S~ao Paulo and Sistema de Informac¸~ao de Agravos de Notificac¸~ao (SINAN).
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survival among all cancers assessed and signiﬁcantly worse in
PWA when compared to non-PWA.11 Our study could not
conduct analysis according to leukemia subtype due to insuf-
ﬁcient number of cases, but it could be possible that the
impaired survival reﬂected the predominance of acute sub-
types, for which prognosis is less favorable.
Wide gaps in survival according to AIDS status were seen
for tumors which are not particularly aggressive in the general
population, namely bladder cancer (HR5 8.11), prostate can-
cer (HR5 6.07) and NMSC (HR5 5.39). Prostate cancer does
not seem to have more severe presentation in HIV-infected
people,25,26 but Riedel et al. observed advanced disease more
frequently in this population.27 As for NMSC, our results are
in line with a previous study, where this malignancy showed
one the greatest survival gaps in Italian patients.11 Evidences
indicate NMSC tends to present in more aggressive forms in
HIV-infected people,28 but elevated HR is likely to be a result
of death from other causes, as NMSC is rarely fatal.
The 1-year overall survival analyses revealed that for sev-
eral cancers, including KS, NHL, lung cancer and leukemia,
the survival gap was restricted to the ﬁrst year after diagnosis,
in agreement with a previous report.11 Findings from the US
revealed that HIV-infected patients were more frequently
diagnosed with distant disease.29 The diagnosis of cancer in
this population can be challenging. Some signs and symp-
toms might be initially mistaken by other morbidities that
commonly affect the HIV-infected, delaying diagnosis. In an
HIV specialty clinic, lung cancer was diagnosed at advanced
stage (III and IV) in 88% of HIV-infected patients as
opposed to 66% of HIV-uninfected controls.21
Suneja et al. compared treatment uptake in HIV-infected
(88.5% PWA) and HIV-uninfected patients with cancer in
the US. HIV-infected patients were less likely to undergo
treatment for cancer. The main predictors for the lack of
treatment among the HIV-infected included distant and
unknown stages, intravenous drug use as exposure to HIV
and older age (45–64 years).29 Another study conducted in
the US found discrepancies in the type of treatment for pros-
tate cancer and HL in HIV-infected when compared to HIV-
uninfected people.24
The inexistence of national guidelines for the diagnosis
and management of malignancies in HIV-infected people in
Brazil could also be associated with low survival rates for
these patients.30 A barrier to the establishment of these
guidelines is that less information on treatment efﬁcacy is
available for NADC in the HIV-infected population because
HIV infection is often an exclusion criterion in randomized
controlled trials.31
Table 4. Hazard ratio of death and corresponding 95% confidence intervals at 5 years, by cancer type, sex and age group. S~ao Paulo, 1997–
2009
Sex Age group
Men Women <40 years 40 years
Cancer type/site n HR (95% CI)1,2 n HR (95% CI)1,2 n HR (95% CI)1,2 n HR (95% CI)1,2
All3 951 2.60 (2.31–2.92) 343 2.66 (2.22–3.20) 602 3.19 (2.71–3.76) 692 2.41 (2.13–2.73)
ADC3 517 3.30 (2.69–4.06) 154 2.23 (1.68–2.95) 408 3.02 (2.42–3.76) 263 2.89 (2.26–3.71)
KS 346 4.07 (2.78–5.97) 27 1.44 (0.56–3.69) 241 4.07 (2.38–6.96) 132 3.52 (2.16–5.75)
NHL 174 2.88 (2.27–3.67) 54 3.63 (2.17–6.08) 121 3.17 (2.34–4.30) 107 2.99 (2.16–4.14)
CC NA NA 73 1.96 (1.18–3.26) 48 2.20 (1.09–4.42) 25 2.19 (1.09–4.42)
NADC3 434 2.3 (1.99–2.68) 189 3.02 (2.37–3.84) 194 3.41 (2.68–4.33) 429 2.28 (1.97–2.64)
Head and neck 56 1.56 (1.11–2.20) 7 10.72 (2.66–43.96) 13 2.28 (0.99–5.27) 50 1.65 (1.16–2.36)
Stomach 14 1.53 (0.79–2.97) 12 2.76 (1.31–5.79) 9 1.95 (0.85–4.49) 17 1.88 (1.01–3.49)
Colon-rectum 21 3.60 (1.89–6.88) 11 2.79 (1.04–7.50) 10 6.48 (1.89–22.18) 22 2.82 (1.48–5.37)
Anus 39 1.91 (1.02–3.60) 4 2.23 (0.53–9.33) 11 8.04 (2.27–28.49) 32 2.04 (1.26–3.29)
Lung 29 3.09 (1.97–4.85) 9 2.66 (1.09–6.50) 8 3.53 (1.36–9.13) 30 2.77 (1.76–4.36)
NMSC 99 5.20 (3.15–8.60) 27 6.18 (2.77–13.76) 36 7.98 (3.17–20.06) 90 4.77 (2.97–7.68)
Breast 1 * 39 2.56 (1.43–4.58) 16 2.22 (0.92–5.38) 24 3.25 (1.47–7.20)
CNS 10 1.94 (0.84–4.47) 7 6.92 (2.15–22.22) 9 10.23 (3.33–31.40) 8 1.64 (0.68–3.94)
HL 29 3.53 (1.93–6.45) 7 1.48 (0.10–21.22) 15 2.99 (0.97–9.20) 21 3.63 (1.76–7.48)
Leukemia 9 1.96 (0.88–4.38) 5 9.10 (2.22–37.35) 8 2.80 (1.23–6.37) 6 3.60 (1.20–10.81)
Abbreviation: NA, not applicable.
1HR stratified by matching variables and adjusted for age (in years) at cancer diagnosis.
2Matched by cancer type (1:1 for KS, 1:2 for NHL, 1:4 for other cancers), sex, age and period of diagnosis.
3People with two primary site cancers were included only once in the analysis.
*HR not available due to insufficient number of events among cases or controls.
Sources: Population-based Cancer Registry of S~ao Paulo and Sistema de Informac¸~ao de Agravos de Notificac¸~ao (SINAN).
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A study assessing death records of PWA in S~ao Paulo
revealed that over 90% of all deaths in the post-HAART era
were still associated with infectious and parasitic agents, espe-
cially tuberculosis (>20%). The same study also identiﬁed
assault as one of the leading underlying causes of death
among PWA in low-income areas of the city.9
Non-adherence to HIV treatment, including routine medi-
cal appointments and use of HAART, could have led to
poorer outcomes. Despite the existence of a healthcare system
free of cost, patients could face barriers to seek care and fol-
low medical treatment.32 In S~ao Paulo, HIV disproportionally
affects vulnerable populations, including sex workers, drug
users, street dwellers and imprisoned people, conditions that
could negatively impact adherence to HIV treatment.33
The strengths of our study are the matching process,
which included histological groups among other variables:
the number of assessed cancer sites and its representativeness.
Matching was an effective tool to ensure comparability of
PWA and non-PWA, as it was shown in previous research.11
Due to the number of cancer cases in PWA our study was
able to include, in addition to ADCs, 22 NADCs in the type/
site-speciﬁc analyses. Survival for some of these cancers has
been poorly documented previously.10,11,23
This is the ﬁrst population-based study estimating survival
after cancer among PWA in Brazil and one of the few in
developing countries. We employed a multi-step record link-
age procedure and clerical review, although time-consuming,
to improve the sensitivity and speciﬁcity of this method.6,34
Our study has also limitations. It was not possible to
include clinical staging of the cases in the analyses, because
this information was available for a small fraction of cases.
Another constraint is that our study was restricted to PWA
diagnosed with cancer in the post-HAART era. As the time
series of the PBCR-SP begins only in 1997, it was not possi-
ble to analyze a longer period and compare survival across
periods as previously done in other countries.10,11 Because
reporting of HIV infection without AIDS was not mandatory
until 2013 in Brazil, some of the controls from the general
population could be HIV-infected, but since the prevalence
of HIV infection in the country is low (0.6% in adults) this
would not greatly affect our results.35 Information on antire-
troviral regimen and CD4 count were also not available
because they are not routinely collected by the AIDS registry
(SINAN).
Since there is no information on smoking status in the
databases used in our study, it was not possible to control
the analysis for this variable. Smoking is strongly associated
with the incidence of cancer as well as early mortality and it
is more frequent among HIV-infected people than in the
general population.36
Lastly, the insufﬁcient number of events in some type/site-
speciﬁc analyses resulted in large conﬁdence intervals, but
since cancer is a rare event, this would not be unexpected.
Our study revealed that there is a signiﬁcant survival gap
between PWA and non-PWA with cancer even after the
introduction of HAART. A number of factors could have
contributed to unfavorable outcomes in PWA, such as dis-
parities in cancer diagnosis, differences in treatment uptake
across populations, lack of speciﬁc treatment guidelines for
the HIV-infected population and death from other causes
including external causes, among others.21,29,37
As in the developed world, an important share of these
cancers is related to life style, especially tobacco smoking and
is preventable.6 Although, Brazil has effectively implemented
strategies to control tobacco at a population level,38 it seems
to have been less successful in reaching the HIV-infected
people. Therefore, approaches targeted at this speciﬁc popula-
tion for preventing cancer, by reducing or eliminating the
exposure to key risk factors should be strengthened. The
assessment and the implementation of speciﬁc screening
guidelines for this population as an attempt to ensure early can-
cer diagnosis should be also considered. As proposed by Goe-
dert et al., physical examination of HIV-infected patients
during routine appointments could be a tool to detect some
malignancies.39 In addition to that, efforts to ensure proper can-
cer treatment in this population should also be emphasized.
In this scenario, patients and healthcare providers would
greatly beneﬁt from the development of national guidelines
for the prevention, early diagnosis and management of cancer
among HIV-infected people.
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